



**Medicinal Products Act, No. 100/2020,  
as amended by Act No. 132/2020, 14/2022 and 29/2024.**

Where mention is made in this Act of ‘the minister’ or ‘the ministry’ without further definition, the reference intended is to the Minister of Health or to the Ministry of Health, which is responsible for the implementation of this Act. Information on the division of responsibilities between ministries according to a presidential decree may be found [here](#).

**SECTION I**

**Objectives, scope and definitions.**

Article 1

*Objectives.*

The objective of this Act is to ensure that the people of Iceland have a sufficient supply of necessary medicinal products, with patient safety as the guiding principle and employing the most efficient means of distribution on the basis of normal competition and in accordance with the rules which apply in the European Economic Area or under the Convention Establishing the European Free Trade Association.

In trading in medicinal products, it must at all times be borne in mind that distribution constitutes part of the health services, and entities involved in distribution shall cooperate with other entities in the health services in striving to achieve the public goals defined in the health services at any given time.

It is, furthermore, the objective of this Act to ensure as far as possible the quality and safety of medicinal products and services, increase public awareness regarding the use of medicinal products, counter their excessive use and keep medicinal product costs to a minimum.

Article 2

*Scope.*

[Unless otherwise specifically stated, this Act shall apply to medicinal products for humans.]<sup>1)</sup>

This Act does not cover medical equipment (*cf.* the Medical Equipment Act), chemicals and chemical mixtures (*cf.* the Chemicals Act), foodstuffs (*cf.* the Foodstuffs Act), tobacco (*cf.* the Tobacco Act) or e-cigarettes (*cf.* the Electronic Cigarettes and Refill Containers Act). This Act, together with the Radioactive Substances Act, shall apply to medicinal products falling under item 8 of paragraph 1 of Article 3 which contain radioactive substances.

In cases of doubt as to whether individual substances or compounds are to be regarded as medicinal products, the Icelandic Medicines Agency shall resolve the issue. If, when all of a product’s properties are taken into account, it is found to come under the definition of a medicinal product as determined by the Icelandic Medicines Agency (*cf.* item 8 of paragraph 1 of Article 3) and also the definition of a product under other legislation, the provisions of this Act shall apply.

<sup>1)</sup> Act No. 14/2022, Article 77.

Article 3  
*Definitions.*

In this Act, the following terms and expressions are used as defined below.

1. *Magistral formula products*: Medicinal products that are manufactured in a pharmacy in accordance with a prescription by a physician.
2. *Manufacture of medicinal products*: All measures aimed at the manufacture of medicinal products, including the purchasing of substances and products and also the production process, such as weighing, mixture, filling of containers, packaging, repackaging, labelling, approval, storage and quality monitoring.
3. *Falsified medicinal products*: Any medicinal product with a false representation of:
  - a. its identity, including its packaging and labelling, its name or its composition as regards its ingredients, including excipients and the strength of those ingredients;
  - b. its origin, including the manufacturer, country of manufacture, country of origin or marketing authorisation holder; or
  - c. its history, including the records and documents relating to the distribution channels used.
4. *Wholesale distribution of medicinal products*: All measures aimed at distributing medicinal products at the wholesale level, including importing, exporting, acquisition and distribution.
5. *Excipients*: Any part of a medicinal product other than the active ingredient and the packaging material.
6. *Herbal medicinal product*: Any medicinal product in which the active ingredients consist solely of one or more herbal substances or one or more fully-processed herbal preparations or a combination of one or more such herbal substances and one or more such herbal medicinal products.
7. *Medicinal products subject to licence*: ‘Medicinal products subject to licence’ refers to medicinal products that may only be used after they have been approved by Landspítali’s Medicinal Products Committee, are normally expensive, require great care in their use and require some sort of expert knowledge and the involvement of healthcare workers, whether this is in connection with their administration or the monitoring of the patient or the medicinal product.
8. *Medicinal product*: All types of substance or combination of substances which:
  - a. are said to have properties that are of use in the treatment of illnesses in humans ...<sup>1)</sup> or in the prevention of illness, or
  - b. which may be administered to humans ...<sup>1)</sup> or given to them, in order to restore, correct or modify physiological functions by means of pharmacophysiological or immunological action or through action on metabolism, or in order to confirm a diagnosis.
9. *Medicinal product advertising*: Any type of advertising or publicity activity, written or oral, involving images, the handing over of medicinal product samples, promotions of medicinal products and meetings for the purpose of encouraging the prescription, handing over, sale or use of medicinal products. Information provided by government authorities to the public regarding medicinal products, e.g. regarding decisions to grant marketing authorisations, medicinal product pricing or whether Icelandic Health Insurance participates in the cost of medicinal products for persons who are health-insured, shall not be considered to be advertising.
10. *Medicinal product prescription portal*: A central message exchange handling the passage of electronic medicinal product prescriptions between their issuers and pharmacies.
11. *Medicinal product prescription*: A declaration by a physician, dentist, veterinarian, nurse or midwife stating that the issuer is prescribing the specific medicinal product in the specified quantity and has given instructions on its dosage and use. The issuer shall certify the prescription by means of his/her signature.
12. *Pharmaceutical care*: An individually-tailored service given by the pharmacist to the patient, aimed at maximising the effect of the patient’s treatment with medicinal products, and so enhancing the patient’s quality of life. It consists of the pharmacist’s stating the aim of the treatment and use of the medicinal product to the patient and seeking the best methods of achieving this aim in collaboration with the patient and other healthcare professionals.

13. *Medicinal product database*: A database operated for the purpose of ensuring quality in the health services and patient safety, maintaining general supervision of prescriptions, supervision of habit-forming and narcotic drugs and sharing information about individuals' medicinal product prescriptions for purposes including enhancing safety in the issue of prescriptions by physicians, maintaining supervision of medicinal product costs and preparing schedules on quality development in the health services and scientific research.
14. *Marketing*: When a medicinal product is made accessible for use, following the issue of marketing authorisation by the Icelandic Medicines Agency or of other comparable authorisation from the agency and the medicinal product meets all the licence requirements. In the case of a prescription product, the agreed maximum price of the medicinal product shall also be published in the medicinal product price list.
15. *Brokering of medicinal products*: All activities in connection with the purchase or sale of medicinal products, other than wholesale distribution, that consist of negotiating business deals independently and on behalf of another legal or natural person, with the exception of handling the products.
16. *Centralised medicinal product card*: An electronic card which grants healthcare professionals and the patient access to electronic information on the treatment of the patient by means of medicinal products at any given time
17. *Intermediate product*: A mixture of active ingredients and excipients intended for further processing in the manufacture of medicinal products.
18. *Parallel importation of medicinal products*: When an entity other than the marketing authorisation holder engages in the importation of, or trading in, a specific medicinal product for which marketing authorisation has been granted.
19. *Retailing of medicinal products*: Retailing of medicinal products which takes place:
  - a. in a pharmacy, where the public is able to purchase medicinal products (both prescription medicinal products and over-the-counter medicinal products), or
  - b. in a shop where the public is able to purchase minimum packages and minimum strengths of nicotine and fluoride medicines.
20. *Homeopathic medicinal product*: Any type of medicinal product that is processed from substances referred to as homeopathic stocks, in accordance with the method of production of homeopathic medicinal products described in the European Pharmacopoeia or, if not there, then in the pharmacopoeias in force in the member states of the European Economic Area.
21. *Officinal formula products*: Medicinal products manufactured in a pharmacy in accordance with a formula in a pharmacopoeia, and which the pharmacy in question hands over to the patient directly
22. *Active substance*: Any substance or mixture of substances that is intended to be used in the manufacture of a medicinal product and that, when used in its production, becomes an active ingredient of that product intended to exert a pharmacological, immunological or metabolic action with a view to restoring, correcting or modifying physiological functions or to make a medical diagnosis.

<sup>1)</sup> Act No. 14/2022, Article 77.

## **SECTION II**

### **Supervision, and the role and responsibilities of the Icelandic Medicine Agency.**

#### *Article 4*

#### *Supervision.*

The minister shall exercise supervision of matters covered by this Act.

#### *Article 5*

#### *The Icelandic Medicines Agency.*

An Icelandic Medicines Agency shall be operated under the supervision of the minister.

The minister shall appoint the director of the Icelandic Medicines Agency for terms of five years at a time. The director shall hold a university degree and have knowledge in the agency's field of operations and

shall have acquired administrative experience. The director shall direct the agency, ensure that it functions in accordance with the acts of law and regulations valid at any given time and be responsible for its day-to-day operations.

Neither the director nor other staff of the Icelandic Medicines Agency may have special and substantial interests at stake in the development, production, marketing, importation, brokerage, wholesaling or retailing of medicinal products.

## Article 6

### *Role of the Icelandic Medicines Agency.*

The role of the Icelandic Medicines Agency shall be as follows:

1. To evaluate medicinal products in accordance with this Act and the rules applying in the European Economic Area and according to the Convention Establishing the European Free Trade Association.
2. To handle the issuing, amendment, temporary suspension and revocation of authorisations for the marketing of medicinal products, together with monitoring the holders of authorisations for the marketing of medicinal products, issuing authorisations for parallel importation of medicinal products and the registration of traditional homeopathic medicinal products, herbal medicinal products and natural medicinal products in accordance with this Act and the rules applying in the European Economic Area.
3. To process applications for authorisation to import and sell, according to prescription, medicinal products that do not have marketing authorisation in Iceland.
4. To receive and register notifications of side-effects of medicinal products from the public, healthcare professionals, veterinarians, keepers of animals and the Directorate of Public Health in the medicinal product prescription portal of the Icelandic Medicines Agency and in the databases of the European Medicines Agency.
5. To grant licences for the manufacture and wholesaling of medicinal products in Iceland, monitor such activities (including the supply of medicinal products in Iceland) and to record details of licences granted for the manufacture and wholesaling of medicinal products in the database of the European Medicines Agency.
6. To grant licences for the sale of medicinal products, and operating licences, and to monitor such activities.
7. To monitor the handling of medicinal products in healthcare institutions and the workplaces of healthcare professionals.
8. To grant licences for, and supervise sales by veterinarians of, medicinal products intended to be used for animals.
9. To operate and supervise the medicinal products reference register.
10. To monitor the importation of medicinal products, pharmaceutical substances and raw materials for the manufacture of medicinal products, or any other products subject to the agency's authority.
11. To monitor the advertising of medicinal products.
12. To monitor narcotic drugs and psychotropic substances under this Act and to carry out the tasks assigned to the agency under the Narcotic Drugs and Psychotropic Substances Act and regulations.
13. To monitor the collection, handling, storage and distribution of blood and the quality and safety of the handling of human cells and tissues.
14. To take decisions on medicinal product pricing, with the objective of this Act, that the use of medicinal products in Iceland be based on a rational and efficient basis, as the guiding principle, and to decide on whether medicinal products qualify for cost participation, as appropriate, under this Act and regulations issued hereunder.
15. To attend to the tasks entrusted to the agency under the Medical Equipment Act.

- [16. To attend to the tasks entrusted to the Agency under the Act on Veterinary Medicinal Products.]<sup>1)</sup>
- [17.]<sup>1)</sup> To monitor the supply of medicinal products in such a way that medicinal product shortages will have the minimum impact on patient safety.
- [18.]<sup>1)</sup> ...<sup>2)</sup>
- [19.]<sup>1)</sup> ...<sup>1)</sup>
- [20.]<sup>1)</sup> To attend to other tasks relevant to the application of this Act, including collaboration with overseas institutions in the field of medicinal products.

The minister may issue regulations entrusting the Icelandic Medicines Agency with the monitoring of other undertakings, other activities or other products apart from medicinal products and related products if particular circumstances favour this and such functions are related to its role under this Act.

The Icelandic Medicines Agency may operate a laboratory to carry out tests and research for the agency. The Icelandic Medicines Agency may furthermore commission independent laboratories in Iceland or abroad to carry out tests or research on behalf of the agency.

The Icelandic Medicines Agency may process personal data, including personal data of a sensitive nature, on individuals' use of medicinal products with a view to ensuring sufficient supply, quality and safety of medicinal products and services and to the monitoring of entities subject to supervision and meeting other responsibilities under this Act, taking account of the obligations imposed by the Personal Data Act.

<sup>1)</sup> Act No. 14/2022, Article 77. <sup>2)</sup> Act No. 29/2024, Article 9.

#### Article 7

##### *Task forces and specialists.*

The Icelandic Medicines Agency may appoint committees and task forces, and call in specialists to advise it, for example in evaluating and classifying medicinal products, conducting supervision and investigations and in taking decisions on medicinal product pricing and participation in the cost of medicinal products.

Specialists called in to assist the Icelandic Medicines Agency, and persons appointed to committees or task forces (*cf.* paragraph 1) may not have special and substantial interests at stake in the development, production, marketing, importation, wholesaling or retailing of medicinal products. The Icelandic Medicines Agency may decide to waive these demands if such a decision is supported by relevant considerations.

### **SECTION III** **Pharmacopoeias.**

#### Article 8

##### *Pharmacopoeias valid in Iceland.*

Iceland is a signatory state of the European Pharmacopoeia and of its protocols. The current English edition of the pharmacopoeia applies in Iceland.

Other demands regarding medicinal product forms, quality and purity, active substances and excipients, and also methods of analysing and standardising these substances, shall be in accordance with a regulation which the minister may set, or with advertisements on the validity of Nordic and other European standards in Iceland.

#### Article 9

##### *Medicinal product registers issued by the Icelandic Medicines Agency.*

The Icelandic Medicines Agency shall maintain a medicinal products reference register. Information shall be recorded in the Medicinal Products Reference Register on the medicinal products that are marketed in Iceland and the medicinal products for which cost participation has been granted. The Medicinal Products Reference Register shall be based on the common names of medicinal products, but shall also contain information on the names of proprietary medicinal products and packagings on the market. All the

information on medicinal products, e.g. regarding their active substances, interactions, indications, contraindications and dosages, shall be accessible to the public, undertakings and public institutions.

The Icelandic Medicines Agency shall supervise the publication of a proprietary medicinal product register. Medicinal products that are placed on the market shall be entered into the Proprietary Medicinal Product Register, grouped by category or in another comparable manner. Information published in the register shall include an approved summary of the properties of the medicinal product and the package leaflet, together with the maximum price of prescription medicinal products. [The Proprietary Medicinal Product Register shall contain information on medicinal products for humans and medicinal products for animals.]<sup>1)</sup>

<sup>1)</sup> Act No. 14/2022, Article 77.

#### Article 10

##### *Other instructions regarding medicinal products.*

European Union guidelines on good manufacturing practice (GMP) in medicinal product manufacture and on good distribution practice (GDP) regarding medicinal products, and other EU guidelines relating to medicinal products that have been adopted in the Agreement on the European Economic Area and the Convention Establishing the European Free Trade Association, shall be valid in Iceland.

Payments covering Iceland's membership of the Pharmaceutical Inspection Convention and the Pharmaceutical Co-operation Scheme shall be borne by the Treasury.

### SECTION IV

#### **Marketing authorisation for medicinal products.**

#### Article 11

##### *Marketing of medicinal products.*

Only medicinal products for which the Icelandic Medicines Agency has granted marketing authorisation may be marketed in Iceland. In the case of prescription medicinal products for human use, the Icelandic Medicines Agency must also have approved a maximum wholesale and retail price, and information on the product must be published in the medicinal product price list. ...<sup>1)</sup>

Without prejudice to paragraph 1, the following medicinal products may be sold in Iceland without a marketing authorisation:

1. ...<sup>1)</sup>
2. Investigational medicinal products that are used in clinical trials of medicinal products on humans.
3. ...<sup>2)</sup>
4. Veterinary medicinal products intended solely for pets, providing that these products do not contain substances the use of which requires supervision by a veterinarian and that all available measures have been taken to prevent their being given without permission to other animals.
5. Magistral formula products and officinal formula products.

Without prejudice to paragraph 1, the following medicinal products may also be sold in Iceland without a marketing authorisation:

1. Traditional herbal medicinal products which have been registered by the Icelandic Medicines Agency.
2. Homeopathic medicinal products which have received marketing authorisation in another member state of the European Economic Area and been registered by the Icelandic Medicines Agency.

<sup>1)</sup> Act No. 14/2022, Article 77. <sup>2)</sup> Act No. 29/2024, Article 9.

#### Article 12

##### *Exemptions.*

The Icelandic Medicines Agency may, in accordance with an application by a physician, in his/her own name or in the name of a healthcare institution, or by [a dentist]<sup>1)</sup>, grant an exemption from the provisions of paragraph 1 of Article 11. Such an exemption shall only be granted if the following conditions are met:

- a. Special circumstances, which are well substantiated with reasons, obtain which call for the use of a medicinal product for which no Icelandic marketing authorisation has been granted, or which has received Icelandic marketing authorisation but has not been marketed in Iceland.
- b. The application states that the quantity for which the exemption is sought is limited to the requirements of those who are to use the medicinal product, and whether the use is intended for a specific individual ...<sup>1)</sup> and whether it will take place in a healthcare institution ...<sup>1)</sup>

When an application according to paragraph 1 is granted, the applicant shall be responsible for informing the patient ...<sup>1)</sup> that the medicinal product being prescribed has not received Icelandic marketing authorisation, and at the same time for informing the patient ...<sup>1)</sup> of possible side-effects and of other matters which may be necessary to know when using the medicinal product. If no marketing authorisation has been granted for the medicinal product in another member state of the European Economic Area, then the physician [or the dentist]<sup>1)</sup> shall be entirely responsible for the prescription and effects of the medicinal product involved.

<sup>1)</sup> Act No. 14/2022, Article 77.

### Article 13

#### *Permits for the compassionate use of medicinal products.*

Without prejudice to the provisions of Article 11, the Icelandic Medicines Agency may, for compassionate reasons, authorise the use of limited quantities of medicinal products for humans for which no marketing authorisation has been granted in Iceland, in accordance with a regulation<sup>1)</sup> issued by the minister setting out the conditions for the granting of authorisation for the use of medicinal products for compassionate reasons.

<sup>1)</sup> Regulation No. 424/2023.

### Article 14

#### *Prescription requirement for medicinal products, authorisation for dispensing and other restrictions.*

In connection with the granting of a marketing authorisation or the granting of a licence for the parallel importation of a medicinal product, the Icelandic Medicines Agency shall decide the following:

- a. whether or not a medicinal product is to be subject to prescription,
- b. whether the use of a medicinal product is to be permitted solely in healthcare institutions which possess the necessary knowledge and skills, facilities and equipment that constitute the premises for the use of the product,
- c. whether the prescription of a medicinal product, a particular dosage size of a medicinal product, a particular length of duration of the administration of a medicinal product or the first prescription of a medicinal product to a patient at the commencement of treatment is to be restricted solely to specialists in specific medical disciplines,
- d. ...<sup>1)</sup>

The Icelandic Medicines Agency may permit the exemption from prescription of a particular quantity or form of a medicinal product which has been decided as being subject to prescription as per indent a of paragraph 1.

The Icelandic Medicines Agency may, at its own initiative or after receiving an application from the marketing authorisation holder or holder of a licence for the parallel importation of a medicinal product, change decisions that have been taken under paragraphs 1 or 2. When taking such decisions, the Icelandic Medicines Agency shall, amongst other things, take account of the conclusions reached by the European Medicines Agency regarding the categorisation of medicinal products in connection with their supply.

<sup>1)</sup> Act No. 14/2022, Article 77.

### Article 15

#### *Validity and renewal of marketing authorisations.*

The ordinary period of validity of marketing authorisations shall be five years. The Icelandic Medicines Agency may limit the period of validity of marketing authorisations if particular circumstances obtain.

A marketing authorisation for a medicinal product may be renewed on the basis of a reevaluation by the Icelandic Medicines Agency showing that the benefit of using a medicinal product outweighs the risks involved. When the marketing authorisation for a medicinal product has been renewed once, it shall remain in force permanently unless the Icelandic Medicines Agency decides, with valid reasons based on pharmacovigilance, that it is to be renewed for five years only.

Marketing authorisation shall lapse if the medicinal product for which it was granted has not in fact been placed on the market within three years of the granting of the authorisation or if the medicinal product for which it was granted has not in fact been on the market for an unbroken period of three years. The Icelandic Medicines Agency may grant exemptions from this provision under special circumstances or for reasons concerning public health. Reasons for such exemptions shall be stated.

#### Article 16

##### *Revocation, suspension or amendment of marketing authorisations.*

The Icelandic Medicines Agency shall revoke, suspend or amend a marketing authorisation if:

- a. it is considered that the medicinal product is harmful or that it does not have a medicinal effect,
- b. it is considered that the benefits of using the medicinal product do not sufficiently outweigh the risks,
- c. the qualitative and quantitative composition of the medicinal product are not regarded as being what they were stated to be when the application for marketing authorisation was made,
- d. the required information submitted with the application for marketing authorisation proves to be incorrect.

The Icelandic Medicines Agency may revoke, suspend or amend marketing authorisations if:

- a. the demands made of the marketing authorisation holder regarding pharmacovigilance under Article 61 are not met,
- b. the time until the utilization of animal products may be resumed following the administration of medicinal products is no longer considered sufficiently long so as to ensure that no medicinal product residues that are harmful to consumers will be present in the animal products,
- c. the manufacture of the medicinal product no longer conforms with the information submitted with the marketing authorisation application for the product,
- d. no quality control is carried out in accordance with the requirements of the valid quality description as provided for in the rules.

A marketing authorisation holder may request at his/her own initiative that the Icelandic Medicines Agency cancel his/her marketing authorisation. When assessing requests from market authorisation holders for the cancellation of their authorisations, the Icelandic Medicines Agency shall take into consideration the impact this would have on the supply of the medicinal product in Iceland.

#### Article 17

##### *[Granting of special authorisation for marketing.]<sup>1)</sup>*

The Icelandic Medicines Agency may, on the basis of a marketing authorisation issued in another member state of the European Economic Area, issue a special licence for the marketing of a medicinal product that has been deregistered, or for which no marketing authorisation has been sought, if the Icelandic Medicines Agency considers it justifiable, in terms of public health considerations or the general public interest, to have the medicinal product in question on the market. If the Icelandic Medicines Agency intends to avail itself of this authorisation, it shall inform the holder of the marketing licence in the country in which the medicinal product is registered of its intention, and also request a copy of the evaluation report and valid marketing authorisation for the medicinal product from the authorities in that country.

<sup>1)</sup> Act No. 14/2022, Article 77.



## Article 18

### *Permission for the temporary distribution of a medicinal product for which no marketing authorisation has been granted.*

The Icelandic Medicines Agency may permit the temporary distribution of a medicinal product for which no marketing authorisation has been granted, providing that it is intended for protection against pathogens, toxic substances, chemical agents or ionizing radiation which are believed, or known, to have spread, or to be capable of having done so.

## Article 19

...

<sup>1)</sup> Act No. 14/2022, Article 77.

## Article 20

### *Obligation of applicants and licensees to provide information.*

Applicants for marketing authorisation, or other types of authorisation, shall be obliged to provide the Icelandic Medicines Agency with all new information regarding the medicinal products for which authorisation is sought, and which are under discussion by the agency, at the first opportunity. The same shall apply in the case of medicinal products for which marketing authorisation, or authorisation of another type, has been granted.

## Article 21

### *Regulations on marketing authorisation and other types of authorisation relating to medicinal products.*

The minister shall issue a regulation<sup>1)</sup> containing further provisions on the granting of marketing authorisation for medicinal products, including the processing of applications, the recognition of centralised marketing authorisations, the retention times applying to materials in pre-clinical and clinical trials, recognition on the basis of marketing authorisation from another member state of the EEA Agreement, changes to the conditions for marketing authorisation, the revocation and cancellation of marketing authorisation and exemptions granted for medicinal products for which marketing authorisation has not been granted in Iceland.

The minister shall issue a regulation containing further provisions on the registration of homeopathic medicinal products and herbal medicinal products, including as regards the processing of applications, registration on the basis of marketing authorisation from another member state in the European Economic Area and definition of traditional use.

The minister may issue a regulation containing further provisions on the conditions for granting authorisation for the parallel importation of medicinal products, including a definition of parallel importation of medicinal products, time limits for the processing of applications for such authorisation, demands regarding materials to be submitted with applications and the labelling of external and immediate packaging and package leaflets accompanying parallel imported medicinal products.

...

The minister may issue a regulation setting out further provisions on the granting of special marketing authorisations for [medicinal products].<sup>2)</sup>

<sup>1)</sup> Regulation No. 545/2018, cf. 1029/505/2019 and 824/2021. <sup>2)</sup> Act No. 14/2022, Article 77.

## SECTION V

### **Clinical trials of medicinal products on humans.**

## Article 22

### *Licences for clinical trials of medicinal products on humans.*

Clinical trials of medicinal products on humans may only be carried out on the basis of a licence. The minister shall issue a regulation<sup>1)</sup> setting out further provisions on the conditions for granting licences for clinical trials of medicinal products on humans. The regulation shall specify the government authority that

is to issue licences for such trials and the role of the authority in evaluating such trials and granting licences. The regulation shall contain provisions on informed consent, how participants in trials are to be insured and the future preservation of materials in clinical trials. The regulation shall furthermore take account of the rules of the European Economic Area applying to such trials, the Helsinki Convention, the Scientific Research in the Health Sector Act and the Data Protection Act.

<sup>1)</sup> Regulation No. 1311/2021, cf. 601/2022 and 343/2023.

## **SECTION VI**

### **Manufacture of medicinal products.**

#### **Article 23**

##### *Manufacture of medicinal products.*

Medicinal products may only be manufactured on the basis of a manufacturing authorisation granted by the Icelandic Medicines Agency.

A manufacturing authorisation for medicinal products shall include authorisation for the wholesale distribution of the medicinal products or types of medicinal products that are specified in the manufacturing authorisation granted to the authorisation holder in question and which it manufactures.

The provisions of paragraph 2 shall not apply to manufacturing by a hospital or other healthcare institution of medicinal products that are used in treatment administered by the institution involved following manufacture. In the case of such manufacture, the Council of Europe's resolutions regarding the manufacture of medicinal products in hospitals or other healthcare institutions shall be taken into account.

#### **Article 24**

##### *Temporary and restricted manufacturing licences.*

The Icelandic Medicines Agency may issue temporary manufacturing licences and restrict licences to a specific type of manufacture.

#### **Article 25**

##### *Manufacturing of active substances.*

Importers, manufacturers and distributors of active substances in Iceland shall register with the Icelandic Medicines Agency.

The Icelandic Medicines Agency shall maintain and publish on its website a list of undertakings covered by paragraph 1. The Icelandic Medicines Agency may strike undertakings off the list if it is found that they have grossly or repeatedly violated the regulations issued under paragraph 1 of Article 27.

#### **Article 26**

##### *Notification obligation concerning falsified medicinal products or active substances.*

All those who have been granted authorisations for the manufacture of medicinal products (cf. paragraph 1 of Article 23) or have registered as manufacturers, importers or exporters of active substances (cf. paragraph 1 of Article 25) shall be obliged to inform the Icelandic Medicines Agency immediately if the party concerned purchases, or is offered for purchase, active substances or intermediate substances that are falsified, or are suspected of being falsified.

#### **Article 27**

##### *Regulations.*

The minister shall issue a regulation<sup>1)</sup> on the manufacture of medicinal products and active substances containing further provisions on the activities of manufacturers, importers or exporters of active substances, including the requirements made concerning specialised knowledge, their organisation, activities and staff, and good working practice in medicinal product manufacture. Furthermore, provisions shall be laid down regarding the requirements made of the authorisation holder's professional director, its premises, equipment and staff, and good manufacturing practice in medicinal product manufacture.

The minister shall set out provisions in a regulation on the conditions for granting manufacturing authorisations for the dose dispensing of medicinal products.

<sup>1)</sup> Regulation No. 699/1996, cf. 484/2001, 846/2002, 546/2018, 906/2022 and 359/2024. Regulation No. 893/2004, cf. 1100/2010, 564/2018, 1028/2018 and 358/2024.

## **SECTION VII**

### **Wholesale distribution of medicinal products.**

#### **Article 28**

##### *Authorisations for the wholesale distribution of medicinal products.*

Medicinal products may only be imported and distributed on a wholesale basis in accordance with a wholesale authorisation granted by the Icelandic Medicines Agency. The minister shall set out further conditions for the granting of wholesale authorisations in a regulation<sup>1)</sup> on the importation, wholesale distribution and brokering of medicinal products, including the requirements made of the authorisation holder's professional director, its premises, equipment and staff and the maintenance of good working methods in medicinal product distribution.

<sup>1)</sup> Regulation No. 699/1996, cf. 484/2001, 846/2002, 546/2018, 906/2022 and 359/2024.

#### **Article 29**

##### *Obligations of wholesale authorisation holders.*

Wholesale authorisation holders who sell medicinal products to pharmacies, healthcare institutions and the workplaces of physicians, dentists and veterinarians shall be obliged to maintain sufficient stocks of specific necessary medicinal products for which marketing authorisation has been granted in Iceland and which have been placed on the market, and of which the wholesale authorisation holder handles the distribution. Following consultation with the Directorate of Public Health, Landspítali or the Food and Veterinary Authority, as appropriate, and a representative of the wholesale authorisation holder, the Icelandic Medicines Agency shall publish on its website a list of the specific necessary medicinal products and stock quantities in question.

Wholesale authorisation holders shall be obliged to record sales information electronically and in a manner approved by the Icelandic Medicines Agency. They shall also provide the Icelandic Medicines Agency and the Directorate of Public Health with information about their activities if requested to do so.

The Icelandic Medicines Agency may prohibit wholesale authorisation holders from selling and exporting specific stocks of a medicinal product from Iceland if it is foreseeable that such exportation could impact the availability of the medicinal product in the country and that this could jeopardize human or animal health.

Wholesale authorisation holders who sell medicinal products to pharmacies, healthcare institutions and the workplaces of physicians, dentists and veterinarians shall maintain and publish medicinal product waiting lists, i.e. lists of medicinal products for which marketing authorisation has been granted in Iceland and which have been marketed, and of which they handle the distribution, but are not available at any given time.

Wholesale authorisation holders shall be obliged to inform the Icelandic Medicines Agency of impending stock shortages of medicinal products.

#### **Article 30**

##### *Authorisations of wholesale authorisation holders.*

Wholesale authorisation holders may only sell medicinal products to the following:

- a. wholesale authorisation holders,
- b. pharmacy licence holders,
- c. holders of authorisations for the sale of veterinary medicinal products (cf. Article 35),
- d. holders of authorisations for the dose dispensing of medicinal products,
- e. healthcare institutions that have a pharmacist in their service,
- f. physicians, dentists and veterinarians for use in their own work,

- g. experimental laboratories and universities which come under the Higher Education Act and which work at medicinal product research and testing and teaching in medicine and pharmacology.

Wholesale authorisation holders may only purchase medicinal products from the following:

- a. other wholesale authorisation holders,
- b. those who are licenced to sell medicinal products wholesale but are exempt from the requirement to hold wholesale licences (*cf.* Article 23).

Wholesale authorisation holders may also sell minimum packages and minimum strengths of nicotine and fluoride medicines (*cf.* paragraph 2 of Article 33).

#### Article 31

##### *Authorisation for the brokering of medicinal products.*

Medicinal products may only be brokered by those who have registered as medicinal product brokers with the Icelandic Medicines Agency.

The Icelandic Medicines Agency shall maintain and publish on its website a list of those who are licensed to broker medicinal products (*cf.* paragraph 1). The Icelandic Medicines Agency may strike medicinal product brokers off this list if it comes to light that they have grossly and repeatedly violated the rules set under paragraph 3.

The minister shall set out further provisions on the registration and activities of those who broker medicinal products in a regulation<sup>1)</sup> on the importation, wholesale distribution and brokering of medicinal products, including as regards the demands made of brokers' specialist knowledge, the organisation of their activities and their staff, and regarding good working practice in medicinal product distribution. The minister shall issue a regulation<sup>2)</sup> on the importation by individuals of medicinal products for their own use, including as regards their interaction with the customs authorities, the police and the Icelandic Medicines Agency in the event of the seizure or the disposal of medicinal products seized by the police in connection with alleged violations of the law.

<sup>1)</sup> Regulation No. 699/1996, *cf.* 484/2001, 846/2002, 546/2018, 906/2022 and 359/2024. <sup>2)</sup> Regulation No. 1277/2022.

### **SECTION VIII ...<sup>1)</sup>**

<sup>1)</sup> Act No. 29/2024, Article 9.

### **SECTION IX**

#### **Retailing of medicinal products, pharmacies, etc.**

##### Article 33

##### *Retailing of medicinal products.*

*[Retailing of medicinal products for humans and medicinal products for animals.]<sup>1)</sup>*

[Medicinal products for humans and medicinal products for animals]<sup>1)</sup> may only be sold to the public under a pharmacy licence issued by the Icelandic Medicines Agency; exemptions are, however, permitted as described in this Section.

Minimum packages and minimum strengths of nicotine and fluoride medicinal preparations that are not subject to prescription requirements may be sold in places other than pharmacies. Medicinal preparations sold under this paragraph may not be offered in selfservice dispensers. The sale of these medicinal products shall furthermore be subject to paragraphs 1 and 7 of Article 8 of the Tobacco Act. The provisions of the Hygiene and Anti-Pollution Measures Act shall apply as regards monitoring, coercive measures and sanctions.

The Icelandic Medicines Agency may grant exemptions from the provisions of paragraph 1 for the sale of specific over-the-counter medicinal products in ordinary shops. Such exemptions may only be granted in localities where no pharmacy, or pharmacy branch, is operated. The Icelandic Medicines Agency shall publish on its website a list of the medicinal products, and their strengths and packagings, that may be sold according to the provisions of this paragraph. The provision of item b of Article 40 shall also apply to those who are granted exemptions of this type.

The Icelandic Medicines Agency may also grant exemptions from the provisions of paragraph 1 for the sale and dispensing of specific medicinal products directly from wholesale authorisation holder or healthcare institution to the public. The Icelandic Medicines Agency shall publish on its website a list of the medicinal products that may be sold under the provisions of this paragraph.

The minister shall set out further provisions on the activities of pharmacies and the conditions for granting pharmacy licences in a regulation<sup>2)</sup> on pharmacy licences and pharmacies, including the demands made regarding licensees' premises, equipment and staff, the operation of pharmacy branches and their classification according to the nature and scope of the services they are permitted to provide, mail-order and internet sales of [medicinal products for humans and medicinal products for animals]<sup>1)</sup> and good working practices in pharmacies.

<sup>1)</sup> Act No. 14/2022, Article 77. <sup>2)</sup> Regulation No. 1340/2022.

#### Article 34

##### *Pharmacy licences.*

The Icelandic Medicines Agency shall grant pharmacy licences. Pharmacy licences may only be granted to those who meet the following conditions:

- a. they must hold valid operating licences as pharmacists in Iceland (*cf.* the Healthcare Practitioners Act),
- b. they must have worked as pharmacists for at least two years, of which at least 12 months shall have been in a pharmacy in the European Economic Area.

The Icelandic Medicines Agency may assess working experience in a pharmacy outside the European Economic Area as being comparable in validity for the purpose of meeting the working experience requirement of indent b of paragraph 1. Furthermore, the Icelandic Medicines Agency may grant a pharmacist's licence to a pharmacist with a minimum of 12 months' working experience as a pharmacist, of which 6 months shall have been in a pharmacy in the European Economic Area if it is considered demonstrated that otherwise there would be no functioning pharmacy in a particular local government area or in a particular urban area within a local government area.

Staff of pharmacies shall be bound by a non-disclosure obligation regarding all matters of which they acquire knowledge, or of which they have a suspicion, regarding illnesses or other personal matters in the course of their work.

Pharmacies shall take on student pharmacists and student pharmacologists for practical training in accordance with agreements with the appropriate educational establishments.

The Icelandic Medicines Agency shall send applications for new pharmacy licences to the relevant local authority for comment. When assessing applications, factors such as the number of persons to be served by the pharmacy and the distance between it and the nearest pharmacy shall be taken into consideration. If the party giving the opinion is opposed to the granting of a new licence, the Icelandic Medicines Agency may reject the application. Applications for pharmacy branches shall be sent to the local authority for comment in the same way.

#### Article 35

##### *Licences for veterinarians to sell veterinary medicinal products.*

In response to applications, the Icelandic Medicines Agency shall grant veterinarians licences to sell veterinary medicinal products if they meet the following conditions:

- a. they must hold valid operating licences as veterinarians in Iceland (*cf.* the Veterinarians and Animal Health Services Act),
- b. they must have informed Icelandic Food and Veterinary Authority that the person concerned has begun operating as a veterinarian and also where their activities take place.

Veterinarians' licences for the sale of veterinary medicinal products shall be limited to the sale and supply of the following veterinary medicinal products for animals which the veterinarian is treating:

- a. over-the-counter veterinary medicinal products,

- b. medicinal products prescribed by a veterinarian (*cf.* the Regulation on veterinarians' authorisation to prescribe medicinal products).

The minister may issue regulations on the sale by veterinarians of medicinal products intended for use on animals.

#### Article 36

##### *Pharmacy licences for health centres.*

The Icelandic Medicines Agency may grant pharmacy licences to the manager of a health centre while no pharmacy is being operated in the local government area, or in a specific urban centre within the local government area, which the health centre serves. Agreements may be concluded with external pharmacy licence holders covering services of this type, including the operation of a pharmacy.

#### Article 37

##### *Operation of pharmacies.*

Pharmacy licences as provided for in Article 34 shall be restricted to the operation of one pharmacy and the licence holder shall be responsible for the operation of the pharmacy. Pharmacies shall be marked in a conspicuous manner.

Pharmacists may hold only one pharmacy licence at any given time. A pharmacy licence holder may apply to the Icelandic Medicines Agency for a licence to operate a branch from his/her pharmacy within the local government area, or in a specific urban area within a local government area where no pharmacy is operated.

Mail-order and internet sales of medicinal products may be made on the basis of a pharmacy licence.

Pharmacies may grant discounts on the maximum retail price of prescription medicinal products. If a pharmacy grants a person covered by health insurance a discount on the price on which cost participation by Icelandic Health Insurance is calculated, Icelandic Health Insurance shall be informed of the discount and shall calculate the price to be paid by the insured person based on the discount price and person's position on the cost steps (*cf.* item 6 of paragraph 1 of Article 29 of the Health Insurance Act).

During normal dispensing hours in pharmacies, and during busy periods outside normal dispensing hours, not fewer than two pharmacists shall normally be on duty, processing prescriptions and giving advice and guidance on the correct use of medicinal products and their handling. The Icelandic Medicines Agency may, in response to an application on this point, permit only one pharmacist to be on duty in a pharmacy, providing that the scope of its operations is small and trained staff assist the pharmacist. The Icelandic Medicines Agency may also, in response to an application on this point, grant a temporary permit for having only one pharmacist on duty in a pharmacy if there is a danger that the operation of the pharmacy in the area in question would otherwise have to be terminated.

#### Article 38

##### *Manufacture of magistral formula medicinal products in pharmacies.*

Pharmacies may manufacture physicians' magistral formula medicinal products and standardised magistral formula medicinal products on the basis of a medicinal product manufacturing authorisation (*cf.* Article 23).

The Icelandic Medicines Agency may grant holders of manufacturing authorisations under Article 23 exemptions from the provision of paragraph 1; thus, magistral formula medicinal products may be manufactured in places other than in pharmacies. An application for exemption shall be made for the manufacture of each specific medicinal product. In an emergency situation where the manufacture is for a specific patient, a notification to the Icelandic Medicines Agency shall be sufficient. Exemptions may only be granted for medicinal products that are considered necessary for patients and when it is not possible to have comparable products with marketing authorisation supplied to Iceland.

Authorisation may not be granted for manufacture if marketing authorisation has been granted for a comparable medicinal product in Iceland.

## Article 39

### *Operating licences.*

If a natural or legal person other than the pharmacy licence holder is the operator of a pharmacy, that person shall be obliged to apply to the Icelandic Medicines Agency for an operating licence.

The operating licence shall contain provisions on the division of roles between the operating licence holder and the pharmacy licence holder as regards which party shall be responsible for compliance with specific provisions of this Act and of regulations issued hereunder.

## Article 40

### *Obligations of pharmacy licence holders.*

Pharmacy licence holders shall be obliged to:

- a. maintain suitable stocks of medicinal products that are on the market in Iceland, obtain, as quickly as possible, medicinal products that are in demand but not in stock and offer for sale the principal types of medical equipment to the extent possible,
- b. provide the Icelandic Medicines Agency with information, as requested by the agency, relating to the activities of the pharmacy,
- c. connect to the central payment database of the Health Insurance Administration and comply with other rules set under the Health Insurance Act, and also to inform the Health Insurance Administration of all instances when the pharmacy grants a discount on the cost participation price of medicinal products that are subject to prescription,
- d. provide the public and healthcare institutions and veterinarians with information about medicinal products, their use and how they are to be stored,
- e. exercise pharmaceutical care,
- f. record, electronically, all information about medical product prescriptions in the form decided upon by the Directorate of Public Health and in accordance with the Data Protection Act, and also to supply the Directorate of Public Health, at its request, with all information contained in a medicinal product prescription concerning the dispensing of the medicinal product in the form desired by the directorate; the Directorate of Public Health may demand this information going back for up to one year in time,
- g. have in their service, as necessary, pharmacy technicians to assist the pharmacy licence holder or other pharmacists working for him/her with the dispensing of prescriptions; the Icelandic Medicines Agency may grant exemptions from this condition under circumstances in which it is not possible to engage pharmacy technicians.

## Article 41

### *[On-line sales of medicinal products for humans and medicinal products for animals.]<sup>1)</sup>*

Pharmacy licence holders (*cf.* Article 34) [and licence holders (*cf.* Article 35)],<sup>1)</sup> who propose to engage in on-line selling of [medicinal products for humans and medicinal products for animals]<sup>1)</sup> on the basis of such licences shall be obliged to notify the Icelandic Medicines Agency of this not later than at the time when on-line sales commence.

The Icelandic Medicines Agency shall maintain and publish on its website a list of pharmacy licence holders who have informed the agency of their intention to engage in online selling of [medicinal products for humans and medicinal products for animals]<sup>1)</sup> as provided for in paragraph 1. The Icelandic Medicines Agency shall also publish on its website information on on-line sales of [medicinal products for humans and medicinal products for animals],<sup>1)</sup> including as regards the potential danger involved in purchasing [medicinal products for humans and medicinal products for animals]<sup>1)</sup> on-line from parties that do not hold the required authorisations.

The minister may issue a regulation<sup>2)</sup> setting more detailed provisions on the conditions for, and the practice of, on-line sales of [medicinal products for humans and medicinal products for animals],<sup>1)</sup> including as regards the information to be submitted with announcements by pharmacy licence holders of their intention to make on-line sales, on the form and content of such announcements, on on-line sales of over-

the counter products within the European Economic Area, on form of, and technical demands made regarding, web pages housing on-line shops for [medicinal products for humans and medicinal products for animals]<sup>1)</sup> and conditions for the publication of the common logo of the EU for on-line pharmacies.

<sup>1)</sup> Act No. 14/2022, Article 77. <sup>2)</sup> Regulation No. 1340/2022.

## **SECTION X**

### **Medicinal product services in healthcare institutions.**

#### **Article 42**

##### *Hospital pharmacies.*

Healthcare institutions operated on the basis of the Health Services Act may operate hospital pharmacies.

The director of the healthcare institution in which a hospital pharmacy is operated shall engage a pharmacist to head the hospital pharmacy; that person shall be responsible for its activities.

The hospital pharmacy shall, amongst other things, be responsible for the procurement of medicinal products, their storage, the maintenance of mandatory registers and monitoring of the use of the medicinal products.

Where necessity so demands, and in particular instances, the Icelandic Medicines Agency may authorise a hospital pharmacy to broker medicinal products to other healthcare institutions and to pharmacies.

If no hospital pharmacy is operated in a healthcare institution that is operated under the Health Services Act, a pharmacist shall be responsible for, amongst other things, the procurement of medicinal products, their storage, the maintenance of mandatory registers and monitoring of the use of the medicinal products.

If the healthcare institution does not have a pharmacist in its service as provided for in paragraph 2, the institution shall enter into an agreement with an external pharmacy licence holder, pharmacist or hospital pharmacy covering services that shall involve responsibility for the procurement of medicinal products and the monitoring of their use.

The premises, equipment and appointment of the staff of hospital pharmacies or medicinal product services in healthcare institutions shall be in accordance with the provisions of this Act and of regulations issued hereunder.

#### **Article 43**

##### *Pharmacies in healthcare institutions.*

Healthcare institutions that are operated under the Health Services Act may operate pharmacies in the healthcare institution in question. The operations of such pharmacies shall be financially separate from other operations within the healthcare institution.

The activities of pharmacies in healthcare institutions shall be restricted to the sale of medicinal products and other products which it is necessary to provide in a pharmacy within a healthcare institution under regulations issued by the minister.

Healthcare institutions may invite tenders for the operation of pharmacies providing that their operation meets all other conditions of this act on the activities and operations of pharmacies.

#### **Article 44**

##### *Landspítali's medicinal products committee.*

A medicinal products committee shall function in Landspítali to promote the safe and rational use of medicinal products at Landspítali and other public healthcare institutions (see, however, Article 45), the aim being to ensure safety in the handling of medicinal products and to ensure that professional and financial responsibility are combined in the choice and use of medicinal products.

The minister shall appoint Landspítali's medicinal products committee for terms of five years. Care shall be taken to ensure that the committee includes persons with an extensive knowledge of clinical medicine, clinical pharmacology, nursing, ethics and finances in the health services. Alternate members of the committee shall be appointed in the same manner. The minister shall set the committee rules of procedure, which shall be published on Landspítali's website.



Landspítali's medicinal products committee shall, amongst other things, take decisions on the use of medicinal products in the health services, including products that are subject to licence, assess whether, and how, medicinal products are of benefit to patients and prepare guidelines for, and priority lists of, medicinal products, taking account of financial allocations for the adoption of medicinal products and their use in the health services. It shall also be the responsibility of the committee to prepare and monitor medicinal product lists for public healthcare institutions.

Landspítali's medicinal products committee shall submit comments to the Icelandic Medicines Agency before the agency takes decisions on classifying medicinal products as being subject to licence. The committee shall also submit comments on participation in the cost of medicinal products that are subject to licence (*cf.* Article 66). Comments shall be written and backed by reasoning. Comments submitted to the Icelandic Medicines Agency shall be accompanied by all the necessary documentation.

Landspítali's medicinal products committee shall take decisions on the share borne by individuals of the cost of medicinal products paid by Landspítali, including as regards medicinal products that are covered by point 4 of paragraph 2 of Article 66. Applications regarding individuals' participation in the cost of medicinal products shall be submitted to Landspítali's medicinal products committee.

Members of the medicinal products committee may not have special and substantial interests in the development, manufacture, marketing, importing, exporting, brokering, wholesaling or retailing of medicinal products.

Landspítali's medicinal products committee shall collaborate closely with the medicinal products committee of the Healthcare Development Centre (*cf.* Article 45) and overseas partners. The committee may also consult other healthcare professions and individual patients' organisations as is deemed necessary.

Decisions of Landspítali's medicinal products committee are final at their administrative level and no appeals may be lodged against them with the minister.

#### Article 45

##### *The Healthcare Development Centre's medicinal products committee.*

A medicinal products committee shall function in the Healthcare Development Centre to promote the safe and rational use of medicinal products that are prescribed or used in health centres (primary clinics) and in nursing and residential homes.

The director of the Healthcare Development Centre shall appoint the medicinal products committee of the Healthcare Development Centre, taking care to ensure that the committee include persons with an extensive knowledge of clinical medicine, clinical pharmacology, nursing and finances in the health services. Alternate members of the committee shall be appointed in the same manner.

The committee's role shall include assessing whether, and how, medicinal products are of benefit to patients and preparing guidelines on the use of medicinal products in the health centres, nursing homes and residential homes.

Members of the medicinal products committee may not have special and substantial interests in the development, manufacture, marketing, importing, brokering, wholesaling or retailing of medicinal products.

The medicinal products committee of the Healthcare Development Centre shall collaborate closely with Landspítali's medicinal products committee (*cf.* Article 44). The committee may also consult other healthcare professions, the University of Iceland's Centre for Ethics and individual patients' organisations as is deemed necessary.

#### Article 46

##### *Regulations.*

The minister shall issue a regulation setting out further provisions on medicinal product services in healthcare institutions and the workplaces of healthcare practitioners, including as regards the selection, storage and handling, use and safety of medicinal products and medicinal product treatment programmes in hospitals, other healthcare institutions and the workplaces of healthcare practitioners where medicinal products are prescribed or used.

The minister shall issue a regulation<sup>1)</sup> on the structure, role and activities of Landspítali's medicinal products committee and the medicinal products committee of the Healthcare Development Centre.

<sup>1)</sup> Regulation No. 1450/2020.

## **SECTION XI**

### **Safety features on the packaging of [medicinal products].<sup>1)</sup>**

<sup>1)</sup> Act No. 14/2022, Article 77.

#### **Article 47**

##### *Safety features on the packaging of [medicinal products].<sup>1)</sup>*

It shall be possible to verify, in the medicinal product supply chain, that individual packages of medicinal products for humans are authentic for the entire time the medicinal product stays on the market and the additional time necessary for returning and disposing of the pack after it has expired.

The minister shall issue a regulation<sup>2)</sup> on safety features on the packaging of [medicinal products].<sup>1)</sup>

<sup>1)</sup> Act No. 14/2022, Article 77. <sup>2)</sup> Regulation No. 140/2019, cf. 164/2021, 309/2022 and 1015/2023.

## **SECTION XII**

### **Medicinal product prescriptions and the dispensing of medicinal products in pharmacies.**

#### **Article 48**

##### *Authorisation to prescribe medicinal products.*

Only holders of valid operating licences as physicians or dentists in the European Economic Area (cf. the Medical Practitioners Act), ...<sup>1)</sup> may prescribe medicinal products.

[The provisions of the Act on Veterinary Medicinal Products apply to veterinary prescriptions for medicinal products.]<sup>1)</sup>

Nurses and midwives who have received special licences from the Directorate of Public Health and work where healthcare, gynaecological or obstetric services are delivered, may prescribe hormone medicinal preparations for contraceptive purposes.

Prescriptions issued by those who are licenced to prescribe medicinal products shall be recorded in the medicinal product database.

Persons licenced to prescribe medicinal products shall promote the responsible use of antibiotics when prescribing medicinal products for patients, with patient safety and the advancement of public health as their guiding principles.

<sup>1)</sup> Act No. 14/2022, Article 77.

#### **Article 49**

##### *Issuing of medicinal product prescriptions; monitoring.*

Medicinal product prescriptions may only be issued as follows:

- a. by electronic prescription prepared in accordance with the Regulation on medicinal product prescriptions and the dispensing of medicinal products,
- b. by a medicinal product prescription written or printed on paper,
- c. by a medicinal product prescription that is read over the telephone and received by a pharmacist in a pharmacy.

The Directorate of Public Health shall monitor medicinal product prescriptions by physicians, dentists, midwives and nurses and dispensing by pharmacists in emergency cases (cf. the Directorate of Public Health Act and Article 75 of the present Act). ...<sup>1)</sup>

<sup>1)</sup> Act No. 14/2022, Article 77.

#### **Article 50**

##### *The medicinal product prescription portal.*

For the transmission of electronic medicinal product prescriptions (cf. indent a of paragraph 1 of Article 49) between the issuers of medicinal product prescriptions and pharmacies, the Directorate of Public Health

shall operate a medicinal product prescription portal. Electronic medicinal product prescriptions may be kept in the portal while they are valid. The Data Protection Act shall apply regarding the processing of personal data sent via the medicinal product prescription portal.

#### Article 51

##### *Dispensing and supply of medicinal products by prescription.*

Medicinal products subject to prescription may only be dispensed by submission of a prescription in a pharmacy. Veterinarians may dispense the medicinal products provided for in Article 35.

Only those who hold valid pharmacists' licences (*cf.* the Medical Practitioners Act) may dispense medical product prescriptions in a pharmacy or pharmacy branch, and the person in question is responsible for the correct dispensing according to the prescription.

In cases of emergency, pharmacists in pharmacies may supply medicinal products that are subject to prescription in the smallest available packages without a prescription being submitted.

Pharmacy licence holders shall keep registers of medicinal products supplied under the authorisation of paragraph 3. Such registers shall be accessible by the Icelandic Medicines Agency and the Directorate of Public Health if this is requested.

#### Article 52

##### *Substitution of medicinal products.*

When dispensing a medicinal product prescription in a pharmacy, pharmacists may change the physician's prescription to another medicinal product of comparable quantity as that prescribed; however, this may only be done if the medicinal product is to be found on the Icelandic Medicines Agency's substitute list (*cf.* paragraph 4).

In special cases, when there is a shortage of a medicinal product that has been placed on the market, the Icelandic Medicines Agency may change a prescription to one for a medicinal product that is permitted by exemption, providing that authorisation of this type is granted following an assessment by the agency of the safety of making such a change.

A physician may, when prescribing a medicinal product (*cf.* Article 48), may restrict, in part or entirely, the right of a pharmacist as laid down in paragraph 1.

The Icelandic Medicines Agency shall maintain and publish on its website a substitute list in which synonym preparations, biosimilars and medicinal products with comparable efficacy in treatment are grouped together listed.

#### Article 53

##### *Regulations.*

The minister shall issue a regulation<sup>1)</sup> setting out further provisions on medicinal product prescriptions and the dispensing of medicinal products in pharmacies, including the design of prescriptions, the prescription of medicinal products, the prescription of medicinal products containing narcotics and psychotropic substances, the Icelandic Medicines Agency's substitute list, dispensing by a pharmacist of a prescription medicinal product in an emergency without submission of a prescription, the period of validity of prescriptions and the labelling of medicinal products in pharmacies, recognised methods of issuing electronic prescriptions and the requirement that prescriptions be recorded in the medicinal products database.

The minister may issue a regulation setting out more detailed rules on the prohibition or restriction of the use of antibiotics for human use.

The minister shall issue a regulation containing more detailed provisions on dentists' authorisations to prescribe medicinal products.

The minister shall issue a regulation setting out further provisions on veterinarians' authorisations to prescribe medicinal products.

The minister shall issue a regulation<sup>2)</sup> setting out further provisions on the conditions for authorisations for nurses and midwives to prescribe medicinal products, including as regards additional study qualifications

and the medicinal products, or medicinal product categories, to which nurses' and midwives' authorisations extend. The Directorate of Public Health may charge a fee for the issue of authorisations to nurses and midwives. Provisions on the fee shall be set out in a regulation.

The minister shall issue a regulation on the medicinal product prescription portal.

<sup>1)</sup> *Regulation No. 233/2001, cf. 490/2001, 248/2002, 848/2002, 480/2005, 516/2006, 789/2010, 513/2012, 624/2012, 138/2017, 808/2018, 105/2021, 310/2022, 1371/2022, 29/2023 and 408/2024. Regulation No. 740/2020, cf. 1279/2021.*

<sup>2)</sup> *Regulation No. 871/2020, cf. 1029/2020.*

### **SECTION XIII**

#### **Medicinal product advertising, projections and healthcare technology assessments.**

##### **Article 54**

##### *Authorisation to advertise medicinal products.*

Medicinal products may be advertised in Iceland, subject to the restrictions set out in this Section.

##### **Article 55**

##### *Information in medicinal product advertisements.*

Medicinal product advertisements shall at all times be presented in a neutral manner and give satisfactory information about the correct use of the medicinal product. Medicinal product advertisements may not be misleading and may not exaggerate, or present misleading information concerning, the properties of a medicinal product. The information in a medicinal product advertisement shall at all times be in accordance with the approved summary of the product's properties.

##### **Article 56**

##### *Prohibited advertising of medicinal products.*

The following may not be advertised:

- a. medicinal products for which marketing authorisation, or authorisation for parallel importing in Iceland, has not been granted,
- b. magistral formula products
- c. officinal formula products.

The following may not be advertised to the public:

- a. medicinal products that are subject to prescription,
- b. medicinal products that contain substances which are covered by the current Narcotics and Psychotropic Substances Act and regulations issued thereunder.

'The public' here refers to all persons other than those who have received operating licences as physicians, dentists, pharmacists, midwives and nurses (*cf.* the Healthcare Practitioners Act) or have received operating licences as veterinarians (*cf.* the Veterinarians and Animal Health Services Act).

The Icelandic Medicines Agency may grant exemptions to make it possible to advertise medicinal products in professional journals of healthcare practitioners other than those listed in paragraph 3.

The Icelandic Medicines Agency may grant exemptions from the provisions of [paragraph 2]<sup>1)</sup> in cases where information is given to the public regarding general measures against infection which the minister has decided are to be taken (*cf.* Section IV of the Health Security and Communicable Diseases Act).

<sup>1)</sup> *Act No. 132/2020, Article 50.*

##### **Article 57**

##### *Obligations of marketing authorisation holders.*

Holders of marketing authorisations shall maintain registers of all their medicinal product advertisements in Iceland. This register shall be preserved for two years and the Icelandic Medicines Agency shall be granted access to on request.

#### Article 58

##### *Monitoring of medicinal product advertisements.*

The Icelandic Medicines Agency shall monitor medicinal product advertisements under this Act.

The Icelandic Medicines Agency may demand that the publication of an advertisement that violates the provisions of this Section, or of a regulation on medicinal product advertising, be stopped.

The Icelandic Medicines Agency may demand that holders of marketing authorisations who have published medicinal product advertisements that violate the provisions of this Section publish corrections or supplementary explanations relating to the unlawful advertisements. The Icelandic Medicines Agency may take a decision laying down requirements regarding the form, content, method of publication and place of publication of such corrections or supplementary explanations.

#### Article 59

##### *Projections and healthcare technology assessments.*

The minister may issue a regulation containing provisions on the conduct of projections and healthcare technology assessments. The regulation shall, amongst other things, define the terms ‘projection’ and ‘healthcare technology assessment’, nominate the government authorities responsible for healthcare technology assessments, lay down rules on the publication of decisions based on healthcare technology assessments and lay down provisions on collaboration with other nations. Government authorities shall take such decisions into account when adopting new medicinal products and technology in the health services.

#### Article 60

##### *Regulations.*

The minister shall issue a regulation<sup>1)</sup> setting out further provisions on medicinal product advertisements, including advertisements for over-the-counter medicinal products and the supply of medicinal product samples, the provision of information and educational guidance on medicinal products for which no marketing authorisation or authorisation for parallel importation has been granted, or which have been granted marketing authorisation but have not been placed on the market, the advertising of medicinal products subject to prescription, the advertising of medicinal products to the public and the necessary information that is to appear in medicinal product advertisements.

The minister shall issue a regulation, after receiving proposals from the Icelandic Medicines Agency, setting rules on the form and substance of the information to be stated in marketing authorisation holders’ registers of medicinal product advertisements, including as regards the target group, contents, use, method of publication and distribution channel.

<sup>1)</sup> Regulation No. 790/2021.

### **SECTION XIV**

#### **Pharmacovigilance.**

#### Article 61

##### *Pharmacovigilance by the Icelandic Medicines Agency.*

The Icelandic Medicines Agency shall operate a pharmacovigilance system to monitor the safety of medicinal products and shall keep a list of side-effects reported to the agency. The Icelandic Medicines Agency may release information on reported side-effects to the Directorate of Public Health, patients’ organizations operating in Iceland, the European Medicines Agency, the European Commission, the competent authorities in the medical product field in member states of the European Economic Area, marketing authorisation holders and the Icelandic Food and Veterinary Authority (MAST), as appropriate.

#### Article 62

##### *Obligations of the marketing authorisation holders.*

Marketing authorisation holders shall be obliged to operate pharmacovigilance systems in order to monitor medical product safety, assess the possibility of minimizing and preventing risks and taking the appropriate measures when necessary.

The Icelandic Medicines Agency may demand that the holder of a marketing authorisation for a medical product for human use nominate a contact person in Iceland who will represent the person responsible for pharmacovigilance.

...<sup>1)</sup>

The Icelandic Medicines Agency shall monitor to ensure that marketing authorisation holders fulfil their obligations under paragraph 1. Marketing authorisation holders shall be obliged to provide the Icelandic Medicines Agency with such materials and information as the agency considers necessary for it to be able to carry out its monitoring functions. Marketing authorisation holders shall furthermore be obliged to grant the Icelandic Medicines Agency access to their premises for the same purpose, should this be necessary in the opinion of the agency.

The Icelandic Medicines Agency shall inform the European Medicines Agency, the European Commission, the competent authorities of other member states of the European Economic Area in the field of medicinal products and the marketing authorisation holder if the outcome of monitoring is that the marketing authorisation does not meet the requirements of the pharmacovigilance system as described in the pharmacovigilance system master file.

If a market authorisation holder ceases to offer a medicinal product on the market, temporarily or permanently, he shall notify the Icelandic Medicines Agency of this. Notifications of this type shall be sent not later than two months prior to ceasing to offer the product on the market unless exceptional circumstances render this impossible. The market authorisation holder shall, to the extent that this falls within his/her responsibility, ensure appropriate and uninterrupted delivery of the product to pharmacies and other entities authorised to dispense the product so as to meet the needs of patients.

<sup>1)</sup> Act No. 14/2022, Article 77.

#### Article 63

##### *Obligations of healthcare practitioners.*

If, in the course of his/her work, a healthcare practitioner comes to suspect that the use of medicinal product is causing serious, new or unexpected side-effects, he/she shall be obliged to notify the Icelandic Medicines Agency of this, using a special form.

...<sup>1)</sup>

Medical practitioners shall be obliged to enable the Icelandic Medicines Agency, the Directorate of Public Health and marketing authorisation holders to send them information on medical product safety, danger warnings and other information based on data from the pharmacovigilance system.

<sup>1)</sup> Act No. 14/2022, Article 77.

#### Article 64

##### *Publication of information on medicinal product safety.*

Marketing authorisation holders for [medical products]<sup>1)</sup> may not publish information on medicinal product safety that is based on pharmacovigilance data without announcing the publication, previously or simultaneously, to the Icelandic Medicines Agency, the European Medicines Agency and the European Commission.

...<sup>1)</sup>

The marketing authorisation holder shall ensure that information under [paragraph 1]<sup>1)</sup> is presented impartially and that it is not misleading.

The Icelandic Medicines Agency may demand that marketing authorisation holders for [medicinal products]<sup>1)</sup> publish medicinal product information relating to patient safety, including information on side-effects which are suspected of being related to medicinal products, or disseminate such information to a specified group of healthcare practitioners.

<sup>1)</sup> Act No. 14/2022, Article 77.

Article 65  
*Regulations.*

The minister shall issue a regulation setting out further provisions on demands made of marketing authorisation holders in connection with pharmacovigilance.

The minister may, in a regulation, set out provisions on the obligation of healthcare practitioners to report to the Icelandic Medicines Agency suspicions of side-effects of the use of a medicinal product, including information from medical records and registers of the causes of death.

The minister may, in a regulation, set out provisions on [the right of patients and their families]<sup>1)</sup> to inform the Icelandic Medicines Agency of side-effects which are suspected of being related to medicinal products.

The minister may issue a regulation on further implementation of the Icelandic Medicines Agency's pharmacovigilance system, including as regards healthcare practitioners' obligation under paragraph 3 of Article 63.

The minister may issue a regulation to respond to shortages of medicinal products, including the obligation of the Icelandic Medicines Agency, healthcare institutions, the Directorate of Public Health and market players to take action to respond to shortages of medicinal products.

<sup>1)</sup> Act No. 14/2022, Article 77.

**SECTION XV**  
**Medicinal product prices and cost participation.**

Article 66

*[Medicinal product and veterinary medicinal product pricing,  
determination of medicinal product prices and cost participation.]<sup>1)</sup>*

The pricing of over-the-counter medicinal products is unrestricted.

The Icelandic Medicines Agency shall determine the following in response to an application:

1. The maximum wholesale and retail prices of medicinal products that are subject to prescription and all veterinary medicinal products, irrespective of whether or not they are subject to prescription. When the Icelandic Medicines Agency takes ordinary decisions on the maximum wholesale prices of medicinal products that are subject to prescription, the agency shall consult representatives of wholesale authorisation holders, and when taking ordinary decisions on maximum retail prices and retail pricing, the agency shall consult representatives of pharmacy licence holders. When taking decisions on the maximum prices of veterinary medicinal products, the Icelandic Medicines Agency shall consult representatives of veterinarians' associations.
2. Whether a medicinal product qualifies for cost participation (*cf.* Section III of the Health Insurance Act on participation by Icelandic Health Insurance in the cost of medicinal products for humans on the market in Iceland) and the cost participation price, i.e., the price on which Icelandic Health Insurance is to base its participation, taking into account any discount granted by the pharmacy licence holder when dispensing a prescription. Before any decision is taken under this point, the Icelandic Medicines Agency shall consult Icelandic Health Insurance. If Icelandic Health Insurance does not respond to a request for consultation within fourteen days of submission of the request, the Icelandic Medicines Agency may take the decision.
3. Whether a medicinal product subject to licence qualifies for cost participation, following prior comment from Landspítali's medicinal products committee. The Icelandic Medicines Agency shall send its application, as soon as possible, to Landspítali's medicinal products committee.
4. Participation in the cost of medicinal products for which exemptions have been granted under Article 12. The Icelandic Medicines Agency may refer the processing of applications in connection with medicinal products for which exemptions have been granted under that provision to Icelandic Health Insurance. Landspítali shall take decisions on participation in the cost of medicinal products for which exemption is granted under paragraph 5 of Article 44.

Before it takes a decision on maximum prices in accordance with point 1 of paragraph 2 and before it decides that a medicinal product may be subject to licence, the Icelandic Medicines Agency shall send the

application to Landspítali's medicinal products committee for comment. The Icelandic Medicines agency shall take its decision when Landspítali's medicinal products committee has delivered its comment. If a medicinal product is considered as being subject to licence, point 3 of paragraph 2 shall apply regarding the application process.

Sellers, i.e. medicinal product wholesalers and market authorisation holders, who wish to sell medicinal products subject to prescription at a price below the stated maximum price shall inform the Icelandic Medicines Agency of that price, which shall publish the reduced price in the next edition of the medicinal products price list. The seller shall sell the medicinal product at the same price at all its points of sale.

Pharmacies, medical product wholesalers and market authorisation holders shall be obliged to provide the Icelandic Medicines Agency with all information regarding medicinal product pricing, and other information, which the agency considers it needs in order to discharge its role under this Section.

Expenses arising from the work of the Icelandic Medicines Agency in connection with the determination of medicinal product prices, decisions on licensing requirements and decisions on cost participation shall be paid by the Treasury.

If the Icelandic Medicines Agency does not agree to a requested official price, a change of price or cost participation under the provisions of this Section, the agency shall give reasons for its decision and inform the applicant of his/her right to refer the agency's decision to the courts. The same applies to decisions by the Icelandic Medicines Agency to classify medicinal products as medicinal products subject to licence.

Decisions taken by the Icelandic Medicines Agency under this Section are final at the administrative level and no appeals may be lodged against them with the minister.

The minister shall issue a regulation<sup>2)</sup> setting out further provisions on medicinal product pricing and participation in the cost of medicinal products, including the requirement that decisions by the Icelandic Medicines Agency are to be based on pricing and cost participation in states, to be specified, in the European Economic Area.

<sup>1)</sup> Act No. 14/2022, Article 77. <sup>2)</sup> Regulation No. 1414/2020, cf. 804/2021 and 196/2023.

#### Article 67

##### *Public procurement of medicinal products.*

Notwithstanding decisions on pricing by the Icelandic Medicines Agency under this Section, those who attend to the procurement of medicinal products for public authorities may tender out, and/or enter into agreements on, the purchase price of medicinal products which the state pays, entirely or in part.

#### Article 68

##### *Criteria when determining medicinal product prices and cost participation.*

The Icelandic Medicines Agency shall, when deciding medicinal product prices, aim at keeping medicinal product costs to a minimum. Consideration shall also be given to the special nature of the Icelandic market for medicinal products and security in medicinal product supply.

The Icelandic Medicines Agency shall take account of medicinal product prices and cost participation elsewhere in the Nordic countries and also in member states of the European Economic Area when taking its decisions.

The Icelandic Medicines Agency shall, when determining the maximum price of medicinal products in parallel importation, take account of factors including the price applied for by the importer, providing this is lower than the price of the same medicinal product in Iceland.

The Icelandic Medicines Agency shall, when deciding the price of synonym preparations, i.e. medicinal products with the same active substance, and biosimilars, take account of the price of the medicinal products in question in the European Economic Area.

#### Article 69

##### *The medicinal product price list and substitute list.*

The Icelandic Medicines Agency shall see to the issue and publication of a medicinal product price list where information shall be published on, amongst other things, the maximum prices and participation in the



cost of medicinal products for humans that are subject to prescription and the maximum prices of all veterinary medicinal products.

The Icelandic Medicines Agency shall see to the issue and publication of a substitute list in which all synonym preparations, biosimilars and medicinal products with comparable efficacy in treatment are grouped together in guideline price categories to make it possible to determine participation in costs.

The minister may issue a regulation<sup>1)</sup> on the medicinal products price list and the substitute list.

<sup>1)</sup> Regulation No. 1414/2020, cf. 804/2021.

## Article 70

### *Processing of applications regarding prices and cost participation.*

Marketing authorisation holders, medicinal product wholesalers and medicinal product brokers shall apply for maximum wholesale prices, cost participation by Icelandic Health Insurance and all changes in the price of medicinal products that are subject to prescription to the Icelandic Medicines Agency, and applications shall be accompanied by information on the wholesale price of the medicinal product in question in the countries specified in the regulation (cf. paragraph 9 of Article 66). The Icelandic Medicines Agency's decision on the medicinal product price shall be available, and shall have been made known to the applicant, not more than 90 days after the application was received. If the applicant fails to provide the necessary information with the application, the agency shall inform the applicant of what information is lacking immediately. The Icelandic Medicines Agency's decision, with reasons, shall then be available, and shall have been made known to the applicant, not more than 90 days after the necessary additional information is received by the agency. If no decision is available by these deadlines, the applicant may place the medicinal product on the market at the price applied for.

If a decision was also sought on participation by Icelandic Health Insurance in the cost of medicinal products for insured persons, such a decision shall be made known within 180 days of receipt of the application regarding the price of the medicinal product. If the applicant has not provided sufficient information with the application, he shall be informed what information is lacking. A decision, with reasons, shall then be available, and shall have been made known to the applicant, not more than 90 days after the necessary additional information is received by the agency. If an application for cost participation is received before the Icelandic Medicines Agency has taken a decision on the medicinal product price, the processing time for the application regarding cost participation shall be extended by a further 90 days.

The Icelandic Medicines Agency's decision on a higher price of a medicinal product shall be available, and shall have been made known to the applicant, not more than 90 days after the application was received. Applicants shall provide the agency with satisfactory information, including detailed information on the points that they consider to justify raising a price that has previously been decided. If the necessary information was not submitted with the application, the Icelandic Medicines Agency shall inform the applicant of what information is lacking. The Icelandic Medicines Agency's decision shall then be available, and shall have been made known to the applicant, not more than 90 days after the necessary additional information is received by the agency. If an abnormally large number of applications have been received by the Icelandic Medicines Agency, it may additionally extend the deadline once by 60 days. Such an extension shall be announced to the applicant before the time permitted to the Icelandic Medicinal Agency to take its decision has elapsed. If no decision has been taken by these deadlines, the applicant may raise the price in accordance with the application.

## Article 71

### *Price freezes.*

The Icelandic Medicines Agency may apply price freezes. If a price freeze is applied to all medicinal products, or to medicinal products in a particular category, then the decision shall be reviewed at least once a year. Exemptions from price freezes may be granted in response to applications in special cases. If the applicant seeks an exemption, he shall provide satisfactory information on the reasons for this request. The Icelandic Medicines Agency's decision, backed with reasons, shall be available, and shall have been made known to the applicant, within 90 days. If the applicant fails to provide the necessary information with the

application, the Icelandic Medicines Agency shall inform the applicant of what information is lacking. The Icelandic Medicines Agency's decision shall then be available, and shall have been made known to the applicant, not more than 90 days after the necessary additional information is received by the agency. If an abnormally large number of applications for exemption have been received by the Icelandic Medicines Agency, it may additionally extend the deadline once by 60 days. Such an extension shall be announced to the applicant before the time permitted to the Icelandic Medicinal Agency to take its decision has elapsed.

#### Article 72

##### *Reassessment.*

The Icelandic Medicines Agency shall reassess the premises for medicinal product pricing in Iceland, comparing pricing with that of the same medicinal products in the European Economic Area regularly and at least every two years, and make proposals regarding amendments if its reassessment gives occasion to do so.

The Icelandic Medicines Agency shall reassess participation in the cost of medicinal products regularly and at least every two years.

The Icelandic Medicines Agency may revise its decisions as to whether a medicinal product is classified as a medicinal product subject to licence.

### **SECTION XVI**

#### **Medicinal product statistics and the medicinal product database.**

#### Article 73

##### *Medicinal product statistics.*

Undertakings which manufacture medicinal products, import them or export them, maintain stocks, negotiate agreements on them resell, distribute, supply, package or repackage them, and companies and firms related to them, shall provide the minister, or an institution nominated by the minister, information on the turnover and quantities of medicinal products sold or supplied. This information shall be in the form requested by the minister or the institution nominated by the minister. Publication of numerical information on turnover and quantities of all medicinal products shall be regarded as provision of this information.

The minister, or the institution that he/she nominates, may release statistical data of a general nature to other entities.

The undertakings mentioned in paragraph 1, and/or their associations, shall furthermore provide the Icelandic Medicines Agency with information on the turnover and quantities of medicinal products sold in electronic format if this is requested.

The Icelandic Medicines Agency, the Directorate of Public Health or Icelandic Health Insurance shall be obliged to supply the minister or the entity nominated by the minister with information and materials on medicinal product sales and releases for presentation and publication of statistical information on medicinal product quantities and turnover.

The minister shall issue regulations on the provision and handling of the information on medicinal products under paragraph 1, including the release and handling of confidential information, the authorisation for the release of data under paragraph 2, the provision of information to the minister under paragraph 3 and the provision of information to the Icelandic Medicines Agency under paragraph 3.

#### Article 74

##### *The medicinal product database.*

The Directorate of Public Health shall operate a medicinal products database covering prescriptions and dispensing of medicinal products and containing data from pharmacists (*cf.* item f of Article 40) for the purpose of ensuring the quality of the health services and patient safety, maintaining general supervision of medicinal product prescriptions, monitoring medicinal products containing narcotic and psychotropic substances and sharing information on medicinal product prescriptions to individuals for purposes including the enhancement of safety in medicinal product prescription by physicians, monitoring medicinal product

costs and preparing projections on quality development in the health services and scientific research. Veterinarians' medicinal product prescriptions shall also be preserved in the database.

The Directorate of Public Health is the entity responsible for the maintenance of the medicinal product database, and each and every entity referred to in this Section shall be responsible for accessing and looking up information in the database in the name of the entity in question.

Patient's personally identifiable features shall be specially encrypted in the medical products database. Encrypted patients' personally identifiable features that are more than 30 years old shall be deleted from the database. The Directorate of Public Health shall be responsible for the encryption of personally identifiable features and it alone shall keep the key to it, both for encryption and de-encryption.

The Data Protection Authority shall, in accordance with its role under the Data Protection Act, monitor the safety of personal data in the medicinal product database and other aspects of the operation of the database.

The minister may specify, in a regulation, the types of data that may be recorded and how it is to be handled.

#### Article 75

##### *Access by the Directorate of Public Health to the medicinal product database.*

The Directorate of Public Health shall have access to the medicinal product database for the purpose of maintaining general supervision of medicinal product prescriptions and monitoring and promoting the rational use of medicinal products in Iceland.

The Directorate of Public Health shall have access to the medicinal product database in accordance with the directorate's supervisory function under the Health Services Act, the Healthcare Practitioners Act the Directorate of Health and Public Health Act and the present Act, when there is reason to believe:

- a. that a patient has been prescribed a greater quantity of medicinal products containing narcotic or psychotropic substances than can be regarded as normal, by one or more physicians;
- b. that a patient has been prescribed a greater quantity of medicinal products containing narcotic or psychotropic substances than can be regarded as normal during a particular period;
- c. that a physician has prescribed himself/herself medicinal products containing narcotic or psychotropic substances, or
- d. that a physician has prescribed a greater quantity of medicinal products containing narcotic or psychotropic substances than can be regarded a normal for one or more patients, or if there is reason to believe that a physician has prescribed medicinal products containing narcotic or psychotropic substances for more patients than can be regarded as normal.

#### Article 76

##### *Access by the Icelandic Medicines Agency to the medicinal product database.*

The Icelandic Medicines Agency shall have access to the medicinal product database for the purpose of maintaining general supervision of the quality, efficacy and safety of the medicinal products that are used in Iceland, including pharmacovigilance monitoring.

The Icelandic Medicines Agency shall have access to the medicinal product database in accordance with the agency's supervisory role under the present Act when there is a reasonable suspicion that:

- a. a medicinal product prescription has been falsified or is unlawful for other reasons,
- b. a medicinal product prescription has been incorrectly, or unlawfully, dispensed.

#### Article 77

##### *Access by the Icelandic Health Insurance to the medicinal product database.*

Icelandic Health Insurance shall have access to the medicinal product database in accordance with the agency's supervisory function under the Health Insurance Act:

- a. when it is necessary to verify information about a patient's medicinal product history in connection with cost monitoring by Icelandic Health Insurance,

- b. in order to examine medicinal product prescriptions and physicians' medicinal product prescription habits in connection with the monitoring of medicinal product expenses.

#### Article 78

##### *Access by the Food and Veterinary Authority to the medicinal product database.*

The Icelandic Food and Veterinary Authority shall have access to the medicinal product database in order to monitor prescriptions by veterinarians and to monitor and promote the rational use of veterinary medicinal products in Iceland.

The Icelandic Food and Veterinary Authority shall have access to the medicinal product database in accordance with the authority's supervisory function under the Veterinarians and Animal Health Services Act when there is reason to believe:

- a. that the keeper of an animal has been prescribed a greater quantity of medicinal products containing narcotic or psychotropic substances than can be considered normal, from more than one veterinarian,
- b. that the keeper of an animal has been prescribed a greater quantity of medicinal products containing narcotics or psychotropic substances than can be considered normal during a specific period, or
- c. that a veterinarian has prescribed himself/herself medicinal products containing narcotics or psychotropic substances.

#### Article 79

##### *Access by physicians, nurses, midwives, pharmacists and dentists to the medicinal product database.*

Physicians, nurses, midwives, pharmacists and dentists who are involved in the treatment of a patient and need to examine his/her medicinal product record in connection with the treatment shall have access to information about the patient's use of medicinal products over the previous seven years in the medicinal product database. The same shall apply to medical students who have completed the fourth year of studies in Medicine in the Faculty of Medicine of the University of Iceland, or comparable studies abroad, and who work under the liability and direction of a healthcare professional who is involved in the treatment of the patient. The Healthcare Practitioners Act, the Patients' Rights Act and other acts of law, as appropriate, shall apply regarding the obligations of these healthcare practitioners and their non-disclosure obligations regarding personal data of a sensitive nature of which they become aware in the course of their work, including information on the use of medicinal products.

#### Article 80

##### *Monitoring and special access to the medicinal product database.*

If, in the course of monitoring by the Directorate of Public Health, Icelandic Health Insurance, the Icelandic Medicines Agency or the Food and Veterinary Authority, suspicion is aroused concerning something which falls under the monitoring function of one of the other institutions, that institution shall be informed of this immediately in order to be able to make the appropriate response.

Information from the medicinal product database may be used for scientific research. The Health Services Research Act and the Data Protection Act shall apply as regards access to personally identifiable information from the medicinal product database.

Furthermore, the ministry may access non-personally identifiable data from the medicinal product database in connection with the taking of decisions and the formulation of policy on medicinal product issues.

The Directorate of Public Health shall maintain active monitoring of access to the medicinal product database under this Section. The Director of Public Health shall set procedural rules regarding access to the medicinal product database. These shall include rules on access control and traceability. If a patient requests information on who has obtained data about him/her from the medicinal product database, the Director of Public Health shall be obliged to provide this information.

Personally identifiable data on individual patients shall not be accessible otherwise than as provided for in this Article unless it is unequivocally necessary in connection with individual monitoring actions or with access by a healthcare practitioner in accordance with Article 79.

#### Article 81

##### *Statistics based on data from the medicinal product database.*

Statistics may be processed from the medicinal product database. When statistical processing is carried out, measures shall be taken to ensure that patients' personal identification features are not accessible. The Directorate of Public Health shall supervise the granting of access to statistical data from the medicinal product database. Access to statistical data from the medicinal product database may only be granted for the following purposes:

- a. for educational and research purposes,
- b. in connection with monitoring of medicinal product costs by public institutions,
- c. in connection with the processing of medicinal product statistics under Article 73.

#### Article 82

##### *Centralised medicinal product cards.*

The Directorate of Public Health shall be responsible for the operation of centralised medicinal product cards.

The Directorate of Public Health shall ensure that patients have access to their medicinal product histories via their centralised medicinal product cards.

Those who are involved in treatment using medicinal products, and pharmacists involved in dispensing medicinal products, shall have access to patients' centralised medicinal product cards.

The Data Protection Act shall apply regarding the processing of personal data in the centralised medicinal product card system.

The minister may issue a regulation<sup>1)</sup> on a centralised database for medicinal product cards, including as regards access to the database, what information may be recorded in the database and how this information is to be handled.

<sup>1)</sup> Regulation No. 1020/2023.

## SECTION XVII

### **Monitoring.**

#### Article 83

##### *Monitoring and its implementation.*

The Icelandic Medicines Agency shall monitor compliance with the provisions of this Act and of regulations issued hereunder, unless otherwise specified. In order to carry out this monitoring or to respond to a request from another member state of the Agreement on the European Economic Area or the Convention Establishing the European Free Trade Association, the Icelandic Medicines Agency may visit any place where activities are pursued on the basis of the following authorisations and licences, registrations or exemptions:

1. A manufacturing authorisation (*cf.* Article 23).
2. Registration as the importer, exporter or manufacturer of an active substance (*cf.* Article 25).
3. A wholesale distribution authorisation (*cf.* Article 28).
4. Registration as a medicinal product broker (*cf.* Article 31).
5. ...<sup>1)</sup>
6. A pharmacy licence (*cf.* Article 34).
7. A licence to sell veterinary medicinal products (*cf.* Article 35).

Entry into residential premises or other similar places for this purpose without the consent of the owner or other person in charge of the premises shall only be permitted under a court order.

Monitoring shall include authorisation to take specimens and photographs, to be given samples of medicinal products without payment, including packaging materials and package leaflets, active substances,

intermediate products or excipients for further examination, and also authorisation to examine and copy materials. Furthermore, the Icelandic Medicines Agency may demand all information and materials that are relevant for monitoring.

A person who is subject to monitoring as provided for in paragraph 1 shall have the opportunity of providing the Icelandic Medicines Agency with information about the medicinal product, active substance, intermediate product or excipient before the investigation begins. The Icelandic Medicines Agency shall allow a suitable period of time for this purpose.

The Icelandic Medicines Agency shall compile a report setting out the findings of the investigation when it is complete.

<sup>1)</sup> Act No. 29/2024, Article 9.

#### Article 84

##### *Authorisations of the Icelandic Medicines Agency; obligations to provide information.*

In connection with examinations and monitoring, including investigations (*cf.* Article 83), all parties under monitoring shall render all assistance necessary for the monitoring without recompense, including assistance by their staff and access to premises and equipment. Furthermore, the Icelandic Medicines Agency shall be provided with all the information it requests, and materials considered by the agency to be relevant to the investigation shall be provided. Other public entities that have information that may be of significance for monitoring shall provide such information at the request of the Icelandic Medicines Agency.

The Icelandic Medicines Agency may call in external specialists for consultation if, in the agency's opinion, this is of significance for monitoring purposes.

#### Article 85

##### *Demands regarding changed working procedures.*

The Icelandic Medicines Agency may demand that licensees and holders of authorisations under Articles 23, 28 and 34-36, and parties subject to registration requirements under Articles 25 and 31 change their working procedures to conform with the provisions of this Act and of regulations issued hereunder. The Icelandic Medicines Agency shall allow a suitable period for them to comply with demands of this type from the agency.

#### Article 86

##### *Information from the customs authorities.*

The Icelandic Medicines Agency may request information from the customs authorities regarding quantities of medicinal products, active substances, intermediate products and excipients, and also quantities from individual manufacturers and importers in connection with the manufacture and importing of medicinal products, active substances, intermediate products and excipients that come under this Act. The provisions of Article 188 of the Customs Act shall not prevent the Directorate of Customs from providing the Icelandic Medicines Agency with information under this Article.

The customs authorities may inform the Icelandic Medicines Agency of medicinal product prescriptions issued by a healthcare professional when there is a suspicion that rules applying to the importation by individuals of medicinal products for their own use have been broken.

#### Article 87

##### *Special authorisations covering monitoring of medicinal product advertisements.*

The Icelandic Medicines Agency may demand that natural and legal persons, and public institutions, provide it with written information relating to suspected violations of the provisions of Articles 55-57, notwithstanding their non-disclosure obligations; this shall be submitted within a suitable period of time decided by the agency. When investigating alleged violations of the provisions of Articles 55-57, the Icelandic Medicines Agency may make the necessary examinations of the natural or legal person's workplace or place where information or materials are kept and seize items, providing there is good reason

to believe that a violation of the provisions has taken place. Provisions of the Code of Criminal Procedure covering searches and the seizure of items shall be observed when measures are taken.

The Icelandic Medicines Agency may release to the government authorities of other member states of the European Economic Area information and materials considered necessary to apply the provisions of Articles 55-57 in accordance with Iceland's obligations under the Agreement on the European Economic Area and the Convention Establishing the European Free Trade Association.

The following conditions shall be set for the release of information and materials:

- a. that the recipient treats the information and materials in confidence;
- b. that the information and materials will only be used for a purpose specified in the Agreement on the European Economic Area or the Convention Establishing the European Free Trade Association and in accordance with the request for information, and
- c. that the information and materials will only be release to other parties with the consent of the Icelandic Medicines Agency and for the purpose specified in its statement of consent.

#### Article 88

##### *Trial purchases.*

The Icelandic Medicines Agency may purchase goods and services under a false name and identity in order to expose violations of Articles 55-57 and to gather information and materials that are considered necessary for the examination of individual cases.

The Icelandic Medicines Agency may demand the refund of sums paid for purchases under paragraph 1 unless this entails substantial inconvenience for the seller.

### **SECTION XVIII**

#### **Fees.**

#### Article 89

##### *Fees according to a tariff of charges.*

The Icelandic Medicines Agency may charge fees for:

1. The issue of marketing authorisations and authorisations for the parallel importing of medicinal products.
2. Amendments to marketing authorisations and authorisations for the parallel importing of medicinal products.
3. Meeting the cost of maintaining the medicinal product registers provided for in this Act, pharmacovigilance, providing information on medicinal products for which marketing authorisation has been granted in Iceland and the necessary collaboration with foreign parties in connection with those medicinal products.
4. Product classification.
5. The agency's monitoring investigations and tests.
6. Scientific counselling and other specialist counselling.
7. Granting exemptions authorising the use of medicinal products for which marketing authorisation has not been granted in Iceland.
8. Issuing licences for clinical trials of medicinal products on humans.
9. Issuing licences and exemptions under the Narcotics and Psychotropic Substances Act.
10. Issuing certificates requested by medicinal product companies.
11. Issuing licences under this Act, other than marketing authorisations and licences for the parallel importation of medicinal products, including a fee reflecting the cost resulting from the work involved in issuing licences, such as the travelling expenses of staff of the Icelandic Medicines Agency within Iceland and abroad and the cost of bringing specialists to Iceland to render assistance.
12. The issuing of the medicinal products price list.
13. Access to the medicinal products reference register.
14. Monitoring of the collection, handling, storage and distribution of blood and of quality and safety in the handling of human cells and tissues.

15. Granting authorisation for the sale of veterinary medicinal products in accordance with item 4 of paragraph 2 of Article 11.
16. Monitoring to ensure compliance with the provisions of Article 47 on safety features on the packaging of medicinal products for humans.

After receiving proposals from the Icelandic Medicines Agency, the minister shall issue a tariff of charges for services provided, monitoring that is not covered by Article 83 and tasks assigned to the agency, or which the agency undertakes to perform under this Act. The amount of each fee shall take account of the cost of the service and the execution of individual tasks and shall be based on a financial budget in which reasoning is given for the determination of each fee. The fee may not exceed costs. The tariff of charges shall be published in Section B of the Government Gazette. Fees may be collected by attachment.

#### Article 90 *Monitoring fee.*

The following shall pay a monitoring fee to meet the cost of regular monitoring by the Icelandic Medicines Agency:

1. Medicinal product manufacturers, including centres where blood collection is carried out and blood-banks.
2. Medicinal product wholesalers.
3. Medicinal product brokers.
4. Pharmacy licence holders.
5. Healthcare institutions and the workplaces of healthcare practitioners.
6. Veterinarians who have been granted licences to sell veterinary medicinal products (*cf.* Article 35).
7. ...<sup>1)</sup>

The monitoring fee shall be determined as follows:

1. Covering the activities of pharmacy licence holders: 0.3% of the total sum paid by Icelandic Health Insurance and/or other public entities to these parties in connection with medicinal product sales during the year preceding the assessment year, or of the total medicinal product procuring amount (the wholesale price without value-added tax) paid by these parties if this amount is higher than that paid by Icelandic Health Insurance and/or other public entities. In no case, however, may the monitoring fee be lower than ISK 250,850 per year.
2. Covering the activities of medicinal product manufacturers, including centres where blood collection is carried out and blood-banks, medicinal product wholesalers, medicinal product brokers, holders of veterinarians' pharmacy licences and holders of special licences for the sale of medicinal products: 0.3% of total medicinal product sales (the wholesale price without value-added tax) during the year preceding the assessment year. In no case, however, may the monitoring fee be lower than ISK 116,870 per year.
3. Covering the activities of veterinarians, healthcare institutions and the workplaces of healthcare practitioners: 0.3% of total medicinal product procurements (the wholesale price without value-added tax) during the year preceding the assessment year. In no case, however, may the monitoring fee be lower than ISK 25,950 per year.
4. ...<sup>1)</sup>

Sums in items 1-4 of paragraph 2 are at the price level in December 2018. Minimum fees under items 1-4 of paragraph 2 shall be revised once a year, on 15 January each year, 70% of their amount following the wage index and 30% following the consumer price index and the price-level revision of the state budget each year. Of the total fees in items 1-4 of paragraph 2, 70% shall be regarded as being due to wage costs and 30% to other costs, and this division shall be observed when sums are revised.

Icelandic Health Insurance, Landspítali and the parties listed in paragraph 1 shall be obliged to provide the Icelandic Medicines Agency with the information needed to levy monitoring fees.

If parties listed in paragraph 1 fail to provide the necessary information, the Icelandic Medicines Agency may assess the monitoring fee. The fee reference base shall be assessed sufficiently high so that there will



be no risk that the amounts assessed will be lower than they are in reality, and the monitoring fee shall then be determined on the basis of that assessment.

A fee that has been levied may be revised if the fee reference base changes. The monitoring fee shall be levied each year, retroactively. The due date for its payment shall be 30 days after the invoice date, and arrears interest shall be calculated from the due date. Determination and calculation of arrears interest shall be in accordance with the Interest and Price Indexation Act. The Icelandic Medicines Agency shall collect fees under this Article, and the fees may be collected by enforcement measures.

<sup>1)</sup> Act No. 29/2024, Article 9.

## **SECTION XIX**

### **Coercive measures.**

#### Article 91

##### *Cautions.*

In order to press for the implementation of measures under this Act, the Icelandic Medicines Agency may give the party in question a caution. At the same time, a suitable period of time shall be granted to take remedial measures if they are needed.

#### Article 92

##### *Per diem fines.*

When a party fails to comply with instructions within a specified period of time, the Icelandic Medicines Agency may impose per diem fines on it until the situation is rectified.

Per diem fines may amount to as much as ISK 500,000 per day. When the amount of a per diem fine is determined, consideration shall be given to factors including the scope and seriousness of the violation, how long it lasted and whether the violation was repeated.

Decisions by the Icelandic Medicines Agency to impose per diem fines may be enforced. If a fine under this Article has not been paid within 30 days of the Icelandic Medicines Agency's decision to impose it, arrears interest shall be paid on the fine amount. Decisions and calculations relating to arrears interest shall be in accordance with the Interest and Price Indexation Act. Uncollected per diem fines, which are imposed up to the final day, shall not be waived even though the party later pays the relevant claim, unless the Icelandic Medicines Agency decides this specially. Fines under this Article shall go to the Treasury following deduction of the costs of their collection.

#### Article 93

##### *Injunctions.*

The Icelandic Medicines Agency may apply for an injunction to protect the overall interests of consumers, providing the other conditions for imposing an injunction under the Act on Seizures, Injunctions (Etc.) are met.

The Icelandic Medicines Agency may have an injunction imposed on an action if it is likely that the conduct involved will substantially damage the overall interests of consumers and no other efficacious course of action is available to prevent violations of Articles 55-57. Injunctions imposed at the request of the Icelandic Medicines Agency may require:

- a. a service provider, or the party operating a network interface, to remove material from the network interface or to set up a clear warning which consumers will see when they open the network interface,
- b. a telecom to restrict access to a network interface,
- c. a service provider to remove, disable or restrict access to a network interface, or
- d. a domain registry or domain registration agency to close or lock a domain or to reregister a domain under the Icelandic Medicines Agency.

Service providers and telecoms may be required to perform actions under paragraph 2 irrespective of whether they are responsible for data, the dissemination of data or the automatic, intermediate or short-term housing of data.

Those who are required to perform actions under items a-d of paragraph 2, and those who are considered to be in violation of the provisions of Articles 55-57, shall have the legal status of injunction respondents where this is possible. If appropriate, the party holding the title to a domain shall be ensured a legal status comparable with that of the injunction respondent for the purpose of defending its interest when the injunction request is considered, and regarding the announcement of the injunction when the consideration is completed, in accordance with Articles 14 and 18 of the Act on Seizures, Injunctions (Etc.), No. 31/1990.

When assessing whether an injunction may be imposed, the interests of the injunction respondent and the overall interests of consumers shall be weighed up. Amongst other things, consideration shall be given to arguments regarding proportionality, freedom of expression and the right to information.

Other aspects of injunctions under this Article shall be subject to the Act on Seizures, Injunctions (Etc.)

#### Article 94

##### *Temporary suspension of marketing of medicinal products.*

The Icelandic Medicines Agency may restrict the marketing of a medicinal product, active substance, intermediate substance or excipient that does not meet the requirements of this Act or of regulations issued hereunder. This means, amongst other things, that the Icelandic Medicines Agency may remove specific medicinal products, active substances, intermediate products or excipients from sale or distribution until deficiencies have been rectified.

#### Article 95

##### *Halting the marketing of medicinal products.*

The Icelandic Medicines Agency may halt the marketing of a medicinal product that does not meet the requirements of this Act or of regulations issued hereunder. This means, amongst other things, that the Icelandic Medicines Agency may remove specific medicinal products, active substances, intermediate products or excipients from sale or distribution, or recall them, permanently, and may seize such products. Furthermore, it may demand that the medicinal product, active substance, intermediate product or excipient in question be destroyed in a secure manner and/or recalled and kept until deficiencies have been rectified or the danger averted in a satisfactory manner.

#### Article 96

##### *Temporary halting of activities.*

If the Icelandic Medicines Agency considers that a particular activity or the use of a medicinal product, active substance, intermediate product or excipient poses such a serious hazard as to necessitate an immediate response on its part, it may halt the activity or use immediately, with police assistance if this is considered necessary.

#### Article 97

##### *Interim decisions.*

In the event of violations of the provisions of Articles 55-57, the Icelandic Medicines Agency may take interim decisions under this Act regarding individual matters, providing there is a danger that the conduct in question will substantially damage the overall interests of consumers.

Interim decisions shall remain valid for a specified length of time and may be extended if this is considered necessary.

#### Article 98

##### *Police assistance.*

The Icelandic Medicines Agency may seek police assistance, if necessary, when applying coercive measures.

## SECTION XX

### Sanctions.

#### Article 99

##### *Confiscation.*

The Icelandic Medicines Agency may confiscate medicinal products, active substances, intermediate products or excipients that do not meet the requirements of this Act or of regulations issued hereunder and destroy them at the expense of the party in charge of them.

#### Article 100

##### *Administrative fines.*

The Icelandic Medicines Agency may levy administrative fines on natural or legal persons that violate:

- a. provisions on the marketing of medicinal products (*cf.* Article 11),
- b. provisions on the obligation of wholesale authorisation holders to provide information (*cf.* Article 20),
- c. provisions on the licensing requirement for medicinal product trials on humans (*cf.* Article 22),
- d. provisions on medicinal product manufacturing (*cf.* Article 23),
- e. provisions on the manufacturing of active substances which are used in the manufacture of medicinal products for humans, and for which marketing authorisation has been granted (*cf.* Article 25),
- f. provisions on notification obligations concerning falsified medicinal products or active substances (*cf.* Article 26),
- g. provisions on the wholesale distribution of medicinal products and the obligations of wholesale authorisation holders (*cf.* Articles 28 and 29),
- h. provisions on the registration obligation of medicinal product brokers (*cf.* Article 31),
- i. ...<sup>1)</sup>
- j. provisions on the retailing of medicinal products (*cf.* Articles 33–37),
- k. provisions on the obligations of healthcare institutions regarding the procurement and storage of medicinal products (*cf.* Articles 42 and 43),
- l. provisions on safety features on the packaging of medicinal products for human use (*cf.* Article 47),
- m. provisions on the issuing of medicinal product prescriptions (*cf.* Article 49),
- n. provisions on the dispensing and supply of medicinal products by prescription (*cf.* Article 51),
- o. provisions on medicinal product advertising (*cf.* Articles 55–57),
- p. provisions on the obligations of marketing authorisation holders as regards pharmacovigilance (*cf.* Articles 62 and 64).

The minister may, in a regulation, determine the monetary amounts of administrative fines for violations of individual provisions of this Act within the framework set out in paragraph 4.

If the monetary amounts of fines have not been determined in a regulation, then when fines are determined, consideration shall be given to factors including the seriousness of the violation, how long it has lasted, whether the perpetrator has demonstrated a willingness to cooperate and whether the violation was repeated. Consideration shall also be given to whether the violation may be regarded as having been committed in the interests of the undertaking and whether it would have been possible to prevent the offence through management and monitoring. The Icelandic Medicines Agency may determine higher fines if the entity has profited by the violation. In such a case, the administrative fine shall be determined as anything up to twice the profit gained through the violation of this Act or of regulations issued hereunder, though within the framework set in paragraph 4.

Administrative fines imposed on natural persons may lie in the range ISK 10,000-10,000,000. Administrative fines imposed on legal persons may lie in the range ISK 25,000-25,000,000.

The due date for the payment of an administrative fine is 30 days after the decision to impose the fine was taken. If the administrative fine remains unpaid 15 days after the due date, arrears interest shall be paid on the fine, calculated from the due date. Decisions by the Icelandic Medicines Agency to impose administrative fines are enforceable and the fines shall go to the Treasury after deduction of the costs of

imposition and collection. Decisions and calculations relating to arrears interest shall be in accordance with the Interest and Price Indexation Act.

Administrative fines shall be imposed irrespective of whether violations are committed on purpose or through negligence.

The party to a case may only bring an appeal against a decision to impose an administrative fine before the courts. The deadline for lodging an appeal is three months from the date on which the decision was taken. Lodging an appeal shall postpone any enforcement measure.

<sup>1)</sup> Act No. 29/2024, Article 9.

#### Article 101

##### *Right to be free from self-incrimination.*

In a case which is directed against an individual, and which may be concluded with the imposition of an administrative fine or a charge made to the police, any person who there is reason to suspect of having broken the law shall have the right to refuse to answer questions or to hand over documents or objects unless it is possible to exclude the possibility that this could be of significance in determining the offence of which he is guilty. The Icelandic Medicines Agency shall give suspected persons guidance concerning this right.

#### Article 102

##### *Prescription.*

The Icelandic Medicines Agency's authorisation to impose administrative fines under this Act shall expire when five years have elapsed from the time that the conduct ceased.

The period provided for in paragraph 1 shall cease to apply when the Icelandic Medicines Agency informs a party of the initiation of an investigation into an alleged violation. Termination of the period shall take legal effect vis-à-vis all those involved in the violation.

#### Article 103

##### *Fines or imprisonment.*

Fines, or imprisonment of up to two years, unless more severe sanctions are prescribed under the present Act or other acts of law, shall be imposed for violations of:

- a. provisions on the marketing of medicinal products (*cf.* Article 11),
- b. Provisions on licensing requirements for clinical trials of medicinal products on humans (*cf.* Article 22),
- c. provisions on the manufacture of medicinal products (*cf.* Article 23).
- d. provisions on the manufacture of active substances to be used in the manufacture of medicinal products for human use for which marketing authorisation has been granted (*cf.* Article 25),
- e. provisions on the notification obligation concerning falsified medicinal products or active substances (*cf.* Article 26),
- f. provisions on the obligations of wholesale authorisation holders (*cf.* Article 29),
- g. provisions on authorisation for brokers of medicinal products (*cf.* Article 31),
- h. provisions on the retailing of medicinal products (*cf.* paragraph 2 of Article 33 and Articles 34-37),
- i. provisions on the issuing of medicinal product prescriptions (*cf.* Article 48),
- j. provisions on the dispensing of medicinal products by prescription (*cf.* Article 51).

Fines, or imprisonment of up to six years, unless more severe sanctions are prescribed under other acts of law, shall be imposed for violations of:

- a. provisions on the wholesale distribution of medicinal products, including medical product importing (*cf.* Article 28),
- b. the provision on the retailing of medicinal products (*cf.* paragraph 1 of Article 33).

Fines may be imposed on legal persons even though it is not possible to demonstrate guilt on the part of their managers or staff or other individuals who work in their service, providing that the violation resulted in, or could have resulted in, an advantage for the legal person. However, legal persons shall not be punished if the violation resulted from an accident. Furthermore, legal persons may be fined in the same way if their

managers or staff, or other individuals who work in their service, are guilty of violations or if a violation results from unsatisfactory equipment or work supervision.

#### Article 104

##### *Criminality, confiscation, attempted violations and accessory capacity.*

Violations of the present Act are punishable by fines or imprisonment, irrespective of whether they are committed on purpose or through negligence.

Profits, direct or indirect, resulting from violations of the provisions of this Act that are punishable by fines or imprisonment, may be confiscated by a court order.

Attempted violations, or acting as an accessory in violations, of this Act shall be punishable according to the provisions of the General Penal Code.

#### Article 105

##### *Authorisation for out-of-court settlements.*

In the event of violations of Articles 55-57, the Icelandic Medicines Agency may conclude the matter by means of an out-of-court settlement, with the consent of the party involved, providing the offence is not a serious one for which sanctions are prescribed. An out-of-court settlement shall be binding on the party when it has been agreed, its substance being confirmed by the party's signature.

In an out-of-court settlement as per paragraph 1, the party may be obliged to offer consumers affected by the offence suitable reparations.

#### Article 106

##### *Charges to the police.*

The Icelandic Medicines Agency may refer violations to the police.

If an alleged violation of this Act is punishable by both administrative fines and sanctions, the Icelandic Medicines Agency shall assess whether to refer the matter to the police or whether it is to be concluded by an administrative decision by the agency. In the event of major violations, however, the Icelandic Medicines Agency shall refer them to the police. Violations shall be regarded as major if the action was committed in a particularly reprehensible manner or under circumstances that seriously increase the criminality of the violation. Furthermore, the Icelandic Medicines Agency may, at any stage of proceedings, refer a case involving violations of this Act for criminal investigation. Consistency shall be observed in the resolution of comparable cases.

Referral to the police of matters by the Icelandic Medicines Agency shall be accompanied by copies of the materials on which the suspicion of a violation is based. The provisions of Sections IV-VII of the Administrative Procedure Act shall not apply to decisions by the Icelandic Medicines Agency to refer matters to the police.

The Icelandic Medicines Agency may provide the police or the prosecutory authority with information and materials that the agency has gathered and are related to violations referred to in paragraph 2. The Icelandic Medicines Agency may participate in police measures related to the investigation of violations referred to in paragraph 2.

The police and the prosecutory authority may provide the Medicines Agency with information and materials that they have gathered and are related to violations referred to in paragraph 2. The police may participate in measures by the Icelandic Medicines Agency related to the investigation of violations referred to in paragraph 2.

If the prosecutor considers there are insufficient grounds for bringing an action over the alleged criminal activity which also falls under administrative sanctions, he/she may send the case back to the Icelandic Medicines Agency for processing and further decision.

## Article 107

### *Authorisation for appeals.*

Unless otherwise specified in this Act, appeals may be lodged with the minister against administrative decisions taken under this Act. The Administrative Procedure Act shall apply regarding the right of appeal and procedure.

## SECTION XXI

### **Miscellaneous provisions.**

## Article 108

### *Ownership of medicinal product undertakings by physicians, dentists, veterinarians, nurses and midwives.*

Practising physicians, dentists and veterinarians may not be the owners of such a large share in an undertaking that is operated on the basis of a medicinal product manufacturing licence, an authorisation for the wholesale distribution of medicinal products, an authorisation for the brokering of medicinal products or a pharmacy licence that this will have an appreciable effect on their financial security. The same shall apply regarding their spouses and children under the age of 18 years

Practising nurses or midwives who are licensed to prescribe medicinal products may not be the owners of such a large share in an undertaking that is operated on the basis of a medicinal product manufacturing licence, an authorisation for the wholesale distribution of medicinal products, an authorisation for the brokering of medicinal products or a pharmacy licence that this will have an appreciable effect on their financial security. The same shall apply regarding their spouses and children under the age of 18 years.

## Article 109

### *Authorisation for issuing regulations.*

The minister shall set out, in regulations<sup>1)</sup>, more detailed provisions on the application of this Act concerning:

1. The collection, handling, storage and distribution of blood (*cf.* item 13 of Article 6).
2. Quality and safety in the handling of human cells and tissues (*cf.* item 13 of Article 6).
3. Conditions for the issue of permits for the compassionate use of medicinal products (*cf.* Article 13).
4. The granting of marketing authorisations for medicinal products (*cf.* paragraph 1 of Article 21).
5. The granting of marketing authorisation for homeopathic medicinal products and herbal medicinal products and their registration (*cf.* paragraph 2 of Article 21),
6. Clinical trials of medicinal products on humans (*cf.* Article 22).
7. The manufacture of medicinal products and active substances (*cf.* paragraph 1 of Article 27).
8. Conditions for the granting of manufacturing licences for the dose dispensing of medicinal products (*cf.* paragraph 2 of Article 27).
9. The importing, wholesale distribution and brokering of medicinal products (*cf.* Article 28 and paragraph 3 of Article 31).
10. The importation by individuals of medicinal products for their own use (*cf.* paragraph 3 of Article 31).
11. ...<sup>2)</sup>
12. Pharmacy licences and pharmacies (*cf.* paragraph 5 of Article 33).
13. The activities of pharmacies in healthcare institutions (*cf.* paragraph 2 of Article 43).
14. Medical product services in healthcare institutions (*cf.* paragraph 1 of Article 46).
15. The structure, role and activities of Landspítali's medicinal products committee and the medicinal products committee of the Healthcare Development Centre (*cf.* paragraph 2 of Article 46).
16. Safety features on the packaging of medicinal products for human use (*cf.* paragraph 2 of Article 47).<sup>3)</sup>
17. Medicinal product prescriptions and the dispensing of medicinal products (*cf.* paragraph 1 of Article 53).
18. Dentists' authorisations to prescribe medicinal products (*cf.* paragraph 3 of Article 53).

19. Veterinarians' authorisation to prescribe medicinal products (*cf.* paragraph 4 of Article 53).
20. Conditions for granting nurses and midwives authorisations to prescribe medicinal products (*cf.* paragraph 5 of Article 53).
21. The medicinal product prescription portal (*cf.* paragraph 6 of Article 53).
22. Medicinal product advertising (*cf.* paragraph 1 of Article 60).<sup>4)</sup>
23. The obligation of marketing authorisation holders to maintain a register of medicinal product advertisements (*cf.* paragraph 2 of Article 60).
24. Demands made of marketing authorisation holders in connection with pharmacovigilance (*cf.* paragraph 1 of Article 65).
25. Medicinal product pricing and cost participation (*cf.* paragraph 9 of Article 66).<sup>5)</sup>

The minister may furthermore set out further provisions on the implementation of this Act in regulations, including as regards the following:

1. Monitoring by Icelandic Medicines Agency (*cf.* paragraph 2 of Article 6).
2. Demands regarding medicinal product forms (*cf.* paragraph 2 of Article 8).
3. Conditions for the granting of authorisation for the parallel importation of medicinal products (*cf.* paragraph 3 of Article 21).
4. The sale of veterinary medicinal products (*cf.* paragraph 4 of Article 21).
5. The sale by veterinarians of medicinal products intended for use on animals (*cf.* paragraph 3 of Article 35).
6. On-line sales of medicinal products (*cf.* paragraph 3 of Article 41).
7. The prohibition or restriction of the use of antibiotics (*cf.* paragraph 2 of Article 53).
8. The obligation of healthcare practitioners to inform the Icelandic Medicines Agency of side-effects that are suspected of being related to medicinal products (*cf.* paragraph 2 of Article 65).
9. The right of patients, their families and the keepers of animals to inform the Icelandic Medicines Agency of side-effects which are suspected of being related to medicinal products (*cf.* paragraph 3 of Article 65).
10. The further implementation of the Icelandic Medicines Agency's pharmacovigilance system (*cf.* paragraph 4 of Article 65).
11. The medicinal products price list and the substitute list (*cf.* paragraph 3 of Article 69).
12. The provision and handling of information on medicinal products in connection with medicinal product statistics (*cf.* paragraph 4 of Article 73).
13. The types of data that may be recorded in the medicinal product database and how it is to be handled (*cf.* paragraph 5 of Article 74).
14. The centralised database for medicinal product cards (*cf.* paragraph 5 of Article 82).<sup>6)</sup>
15. The monetary amount of administrative fines (*cf.* paragraph 2 of Article 100).

The minister may publish, as a regulation<sup>7)</sup>, the rules of the European Union on the European Medicines Agency and also regulations on the European Union's rules on medicinal product issues, with adaptations taking account of the EEA Agreement and the Convention Establishing the European Free Trade Association.

The minister may refer to the foreign original editions of regulations when giving effect to the European Union's regulations that are adopted in the Agreement on the European Economic Area through the simplified procedure. The foreign original edition shall be published in Series C of the Government Gazette.

<sup>1)</sup> Regulation No. 1340/2022. Regulation No. 441/2006, *cf.* 1024/2007, 411/2010, 625/2012, 216/2016, 482/2018 and 407/2024. <sup>2)</sup> Act No. 29/2024, Article 9. <sup>3)</sup> Regulation No. 140/2019, *cf.* 164/2021, 309/2022 and 1015/2023. <sup>4)</sup> Regulation No. 790/2021. <sup>5)</sup> Regulation No. 1414/2020, *cf.* 804/2021. <sup>6)</sup> Regulation No. 1020/2023. <sup>7)</sup> Regulation No. 1264/2017, *cf.* 779/2022. Regulation No. 1311/2021, *cf.* 601/2022 and 343/2023. Regulation No. 785/2022, *cf.* 1276/2022, 103/2023, 317/2023, 342/2023, 1107/2023, 1258/2023 and 207/2024. Regulation No. 228/2024.

**SECTION XXII**  
**Implementation and commencement.**

Article 110

*Implementation.*

This Act is passed in order to implement in Icelandic law the following acts, with their amendments to date:

1. Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems.
2. Council Regulation (EC) No. 297/95 of 10 February 1995 on fees payable to the European Agency for the Evaluation of Medicinal Products.
3. Regulation (EC) No. 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products.
4. ...<sup>1)</sup>
5. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use.
6. Directive 2002/98/EC of the European Parliament and of the Council of 27 January 2003 setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Directive 2001/83/EC.
7. Commission Directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use.
8. Directive 2004/23/EC of the European Parliament and of the Council of 31 March 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells.
9. Directive 2004/24/EC of the European Parliament and of the Council of 31 March 2004 amending, as regards traditional herbal medicinal products, Directive 2001/83/EC on the Community code relating to medicinal products for human use.
10. Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use.
11. Regulation (EC) No 273/2004 of the European Parliament and of the Council of 11 February 2004 on drug precursors.
12. Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency.
13. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004.
14. Regulation (EC) No 1902/2006 of the European Parliament and of the Council of 20 December 2006 amending Regulation 1901/2006 on medicinal products for paediatric use.
15. Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004.
16. Directive 2009/35/EC of the European Parliament and of the Council of 23 April 2009 on the colouring matters which may be added to medicinal products (recast).
17. Directive 2009/53/EC of the European Parliament and of the Council of 18 June 2009 amending Directive 2001/82/EC and Directive 2001/83/EC, as regards variations to the terms of marketing authorisations for medicinal products.
18. Commission Directive 2009/120/EC of 14 September 2009 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use as regards advanced therapy medicinal products.



19. Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use.
20. REGULATION (EU) No 1235/2010 of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, and Regulation (EC) No 1394/2007 on advanced therapy medicinal products.
21. Directive 2011/62/EU of the European Parliament and of the Council of 8 June 2011 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use, as regards the prevention of the entry into the legal supply chain of falsified medicinal products.
22. DIRECTIVE 2012/26/EU of the European Parliament and of the Council of 25 October 2012 amending Directive 2001/83/EC as regards pharmacovigilance.
23. Regulation (EU) No 1027/2012 of the European Parliament and of the Council of 25 October 2012 amending Regulation (EC) No 726/2004 as regards pharmacovigilance.
24. Regulation (EU) No 1258/2013 of the European Parliament and of the Council of 20 November 2013 amending Regulation (EC) No 273/2004 on drug precursors.
25. Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC.
26. Regulation (EU) No 658/2014 of the European Parliament and of the Council of 15 May 2014 on fees payable to the European Medicines Agency for the conduct of pharmacovigilance activities in respect of medicinal products for human use.
27. Directive 2012/26/EU of the European Parliament and of the Council of 25 October 2012 amending Directive 2001/83/EC as regards pharmacovigilance.
28. [28. Regulation (EU) No 2019/5 of the European Parliament and of the Council of 11 December 2018 amending Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, amending Regulation (EC) No 1901/2006 on medicinal products for paediatric use and amending Directive 2001/83/EC on the Community code relating to medicinal products for human use.]<sup>1)</sup>

<sup>1)</sup> Act No. 14/2022, Article 77.

#### Article 111

##### *Commencement.*

This Act takes effect on 1 January 2021. However, paragraph 5 of Article 53 and Article 79 take immediate effect.

...<sup>1)</sup>

Regulations issued under the Medicinal Products Act, No. 93/1994, shall remain in force to the extent that they are compatible with the present Act.<sup>1)</sup>

<sup>1)</sup> See now: Regulation No. 421/1988, cf. 539/2000, 91/2001, 105/2001, 111/2001 and 233/2001. Regulation No. 633/1994. Regulation No. 650/1996. Regulation No. 539/2000, cf. 912/2000, 14/2008, 1069/2008, 392/2012, 931/2012 and 661/2015. Regulation No. 967/2000. Regulation No. 850/2002. Regulation No. 241/2004, cf. 255/2016. Regulation No. 443/2004, cf. 907/2004 and 1099/2010. Advertisement No. 902/2004. Regulation No. 441/2006, cf. 1024/2007, 411/2010, 625/2012, 216/2016 and 482/2018. Regulation No. 1188/2008, cf. 453/2017. Regulation No. 142/2011. Regulation No. 1022/2011. Regulation No. 412/2012. Regulation No. 652/2015. Regulation No. 340/2016, cf. 526/2018. Regulation No. 452/2017. Regulation No. 1265/2017. Regulation No. 541/2018. Regulation No. 546/2018. Regulation No. 477/2019. Regulation No. 1143/2019.

Article 112  
*Amendments to other acts of law.*

...

**Interim provisions.**

**I.**

All positions at the medicinal products pricing committee shall be abolished on the commencement of this Act. All employees of the medicinal products pricing committee shall be offered employment at the Icelandic Medicines Agency or Landspítali, as appropriate, as of the same date. The provisions of Article 7 of the Rights and Obligations of Government Employees Act, No. 70/1996, shall not apply to the disposal of job positions under this provision.

The Icelandic Medicines Agency shall, as from the commencement of this Act, take over the assets of the medicinal products pricing committee and also its rights and obligations regarding the implementation of the acts of law that come under the committee's purview at that time.

**II.**

Authorisations for the manufacture, importing and wholesaling of medicinal products, and pharmacy licences, granted under the Medicinal Products Act, No. 93/1994, shall remain in force. Undertakings that manufacture active substances to be used in the manufacture of medicinal products for human use and have marketing authorisations, and undertakings and individuals who engage in the brokering of medicinal products shall register with the Icelandic Medicines Agency under the present Act before 1 January 2022.

Veterinarians shall apply for special licences to sell veterinary medicinal products by 31 August 2021 (*cf.* Article 35), or else notify the Icelandic Medicines Agency that they do not intend to continue selling such products. Current veterinarians' licences for the sale of such medicinal products shall remain valid until 31 December 2021.

*[This translation is published for information only.  
The original Icelandic text is published in the Law Gazette.  
In case of a possible discrepancy, the original Icelandic text applies.]*